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Introduction 
INTRODUCTION 
 
The restless legs syndrome (RLS) is a neurological disorder characterized by the urge to 
move the extremities associated with paresthesias, which are partially or totally relieved by 
movement, a worsening of symptoms at rest and in the evening or at night and, as a 
consequence, sleep disturbances1. RLS is a common but often under-diagnosed 
sensorimotor disorder of sleep/wake motor regulation with prevalence rates estimated from 
population surveys between 1 and 10%, increasing with age and considerably more 
prevalent in females than males2. There exist many forms regarding the clinical course of the 
disease, the severity and circadian expression of symptoms as well as associated features.   
The first documented description of restless legs associated with severe sleep disturbances 
dates back to the 17th century and was reported by the English physician Sir Thomas Willis. 
Originally published in Latin in 16723 it was later published in English in the London Practice 
of Physick4: 
“Wherefore to some, when being a Bed they betake themselves to sleep, presently in the 
Arms and Legs Leapings and Contractions to the Tendons, and so great a Restlessness 
and Tossing of their Members ensue, that the diseased are no more able to sleep, than if 
they were in a Place of the greatest Torture” (p. 404). 
In the 19th and 20th century several other names were given to the disorder such as anxietas 
tibiarum by Wittmaack5 and leg jitters by Allison6. Karl Axel Ekbom was the first to provide a 
detailed description of the clinical features of the disorder7 and first named it asthenia crurum 
paraesthetica. In 19458 he coined the term restless legs syndrome (RLS) to distinguish it 
from other similar conditions and already reported that the syndrome may cluster in families 
and that there might be a secondary form of RLS in anaemia or pregnancy. In recognition of 
Ekbom’s major contribution to the understanding of this condition, RLS has also been 
referred to as Ekbom syndrome. Alternate names include focal akathisia of the legs9, 
although this term is used very infrequently nowadays. Scientific interest was slow to 
respond to RLS in earlier years but picked up considerably during the 1980s when Akpinar 
reported that RLS was treated successfully with levodopa10 which remained first line 
treatment for nearly two decades. Scientific developments were further helped along by the 
foundation of the International RLS Study Group (IRLSSG) that in 1995 defined uniform and 
internationally accepted criteria for the diagnosis of RLS11 which were updated in 20031.  
Today, most authors agree that RLS has its origin in the central nervous system, however, 
complex interactions between central and peripheral structures may contribute to the 
disorder. Based on the knowledge of the efficacy of dopaminergic and opioidergic drugs and 
the provocation or exacerbation of RLS symptoms following treatment with dopamine 
receptor blocking agents, there is evidence of the involvement of the dopaminergic and 
opioid system in the pathogenesis of RLS. Recent PET and SPECT studies revealed some 
controversial results of the nigrostriatal dopaminergic neurotransmission probably reflecting a 
dysfunction of the central dopaminergic system12. The aetiology, however, remains unclear, 
despite what is known about the conditions that may induce the syndrome13,14. 
 
Diagnosis of RLS 
In 1995, the International RLS Study Group developed standardized criteria for the diagnosis 
of RLS11 which have been recently modified1 and correspond to the criteria of the revised
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Table 1. Diagnostic criteria for RLS (from reference 1) 
 Essential diagnostic criteria for RLS (adults) 
1 An urge to move the legs, usually accompanied or caused by uncomfortable and unpleasant 
sensations in the legs 
2 The urge to move or unpleasant sensations begin or worsen during periods of rest or inactivity 
such as lying or sitting 
3 The urge to move or unpleasant sensations are partially or totally relieved by movement, such 
as walking or stretching, at least as long as the activity continues  
4 The urge to move or unpleasant sensations are worse in the evening or night than during the 
day or only occur in the evening or night 
 Supportive clinical features of RLS 
1 Family history 
The prevalence of RLS among first-degree relatives of people with RLS is 3 to 5 times greater 
than in people without RLS. 
2 Response to dopaminergic therapy 
Nearly all people with RLS show at least an initial positive therapeutic response to either L-dopa 
or a dopamine-receptor agonist at doses considered to be very low in relation to the traditional 
doses of these medications used for the treatment of Parkinson disease. This initial response is 
not, however, universally maintained. 
3 Periodic limb movements (during wakefulness or sleep) 
Periodic limb movements in sleep (PLMS) occur in at least 85% of people with RLS; however, 
PLMS also commonly occur in other disorders and in the elderly. In children, PLMS are much 
less common than in adults. 
 Associated features of RLS 
1 Natural clinical course 
The clinical course of the disorder varies considerably, but certain patterns have been identified 
that may be helpful to the experienced clinician. When the age of onset of RLS symptoms is less 
than 50 years, the onset is often more insidious; when the age of onset is greater than 50 years, 
the symptoms often occur more abruptly and more severely. In some patients, RLS can be 
intermittent and may spontaneously remit for many years. 
2 Sleep disturbance 
Disturbed sleep is a common major morbidity for RLS and deserves special consideration in 
planning treatment. This morbidity is often the primary reason the patient seeks medical 
attention. 
3 Medical evaluation/physical examination 
The physical examination is generally normal and does not contribute to the diagnosis except for 
those conditions that may be comorbid or secondary causes of RLS. Iron status, in particular, 
should be evaluated because decreased iron stores are a significant potential risk factor that 
can be treated. The presence of peripheral neuropathy and radiculopathy should also be 
determined because these conditions have a possible, although uncertain, association and may 
require different treatment. 
 
international classification of sleep disorders9 (ICSD-2). RLS is characterized by: 1) an 
imperative desire to move the extremities which is 2) at least temporarily relieved with 
movement, and 3) worse or exclusively present at rest and 4) in the evening or at night 
(Table 1). Supportive clinical features for RLS are a positive family history for RLS, an initial 
response to dopaminergic therapy and the presence of periodic limb movements during 
sleep (PLMS). The clinical course of the disorder varies considerably and in some patients 
RLS can be intermittent and may spontaneously remit for many years15,16. To diagnose RLS 
in pediatric patients, the child meets four essential adult criteria for RLS and is in addition 
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either able to relate an indicative description in his or her own words or at least two of the 
following criteria are met: a sleep disturbance, a biological sibling or parent with definite RLS, 
or more than five periodic leg movements per hour of sleep, documented by 
polysomnography. Diagnostic criteria in other special populations such as the cognitively 
impaired elderly have also been proposed1.  
Subjects with RLS typically complain about disturbed sleep and in particular about disturbed 
sleep onset due to the restless legs symptoms occurring in the evening and at times of 
inactivity. Most RLS patients will be able to describe clearly the urge to move and the 
associated paresthesias although the clinician is bound to hear a broad range of creative 
descriptions of the symptomatology. Typical examples are “crawling ants”, “jittery legs”, 
“moving worms”, or “soda bubbling in the veins”1. In unclear cases, the suggested 
immobilization test (SIT), which may elicit and quantify the motor symptoms (involuntary leg 
movements) of RLS, may be helpful17. Improvement of symptoms with a single dose of 
levodopa has a high sensitivity and specificity in subjects with RLS and this response is 
considered as a supportive feature18. 
A laboratory evaluation including serum ferritin, electrolytes, and renal parameters can rule 
out potentially secondary forms of RLS such as iron deficiency anemia19,20 or renal failure21.  
In an atypical presentation or when symptoms resemble peripheral neuropathy, nerve 
conduction velocities and electromyogram should be performed. Polysomnography is 
generally reserved for patients where other or additional sleep disorders are suspected or 
where the degree of sleep disturbances needs to be quantified, e.g., for judicial purposes. In 
addition, because opioids can worsen pre-existent sleep related breathing disorders (SRBD) 
polysomnography may be warranted to rule out SRBD before treatment with opioids is 
initiated22,23.  
A number of conditions other than RLS must be considered in the differential diagnosis of 
altered sensations in the legs. These include disorders of the peripheral nervous system 
such as peripheral neuropathies24 and syndromes owing to irritation of the nerve root or 
compression of peripheral nerves25, and vascular conditions such as peripheral arterial 
disease. Altered sensations in the legs and motor restlessness are also reported in patients 
with antipsychotic-induced akathisia26, anxiety disorders and attention deficit hyperactivity 
disorder. In addition, several drugs can induce RLS and in particular antidepressants27 and 
antipsychotics28 have been associated with RLS. 
Chronic RLS is associated with significantly reduced quality of life and within the different 
domains of quality of life the areas “energy / sleepiness” and “performance” are particularly 
impaired29-31. Investigations in different populations such as the general population or sleep 
lab populations revealed that about one third of RLS subjects perceive themselves as being 
excessively sleepy during the daytime32. Considerably less is known about performance 
deficits in subjects with RLS. So far, there have been four fully published studies on cognitive 
functioning in RLS patients33-36. Taken together, these studies suggest cognitive deficits in in 
the area of attention and executive functioning in subjects with clinically significant RLS. We 
have contributed to a further characterisation these deficits by assessing a broad range of 
cognitive functions in unmedicated RLS subjects and explored potential determinants of 
cognitive deficits in this patient group (see CHAPTER II). 
 
Pathophysiology of RLS 
The underlying pathogenesis of RLS is currently unknown37. Major hypotheses centre around 
dopamine and iron while some evidence also implicates the opioid system, spinal cord 
mechanisms, sexual steroid hormones, peripheral neuropathy, or a possible vascular 
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genesis. Very recently, results from the first genome-wide association studies have added to 
the complex picture of RLS pathophysiology. 
There is evidence for a role of iron in RLS, mostly based on the involvement of iron 
insufficiency in cases of secondary RLS (e.g. end stage renal disease, pregnancy and iron 
deficiency)38. In addition, studies using CSF measurements39, MRI40 or autopsy material41 to 
determine the brain iron status in RLS subjects indicate the influence of a low brain iron 
content in RLS. Most interestingly, iron is a co-factor of tyrosine hydroxylase, the rate-limiting 
enzyme for the dopamine synthesis. Thus, iron is needed for dopamine synthesis and in 
case of deficiency may impair the normal production of dopamine. 
The striking pharmacological response to low-dose dopaminergic medications42 and the 
worsening of symptoms with dopamine release blocker43 argues for a primary role of 
dopamine in the pathophysiology of RLS. However, functional neuroimaging of nigrostriatal 
dopaminergic dysfunction in patients with idiopathic RLS has produced conflicting results and 
overall no obvious dopaminergic deficit in RLS37.  This is supported by pathological 
examinations in RLS patients where no dopaminergic cell loss was found41. Neuroendocrine 
responses to challenges with dopaminergic agents (inhibition of prolactin, increase in human 
growth hormone) or dopamine-blocking substances revealed a normal response in the 
afternoon to a dopamine antagonist44. However, neuroendocrine response to a levodopa 
challenge was more pronounced during the night in comparison to the morning in RLS 
subjects45. This might suggest a hypersensitivity of dopamine receptors at night, the time of 
maximal expression of RLS symptoms. In summary, the response to dopaminergic agents is 
probably one of the most closely associated features of RLS. Finding a marker for an altered 
dopamine system in RLS has proven to be more difficult, and it seems likely that the 
dopamine system is predominantly involved in the circadian expression of restless legs 
symptoms.  
The most convincing evidence regarding an involvement of the opiate system, is also based 
on the effectiveness of opioidergic treatment in RLS46,47. Challenges of the opiate system in 
RLS patients48 showed that administration of naloxone to opiate-treated patients reactivates 
RLS symptoms, while it has no consistent effect in subjects treated with dopaminergic 
agents. The challenge of untreated RLS patients with naloxone seems to have no adverse 
effects on RLS symptoms48. Furthermore, untreated RLS patients showed a normal 
hormonal response (increases in hGH, cortisol, adrenocorticotropic hormone (ACTH)) 
following naloxone challenge44. Current definitions1 do not include a painful component of 
RLS sensory symptoms but they recognize that painful sensations can be part of RLS and in 
independent studies the percentage of RLS patients that described their symptoms as painful 
ranged from 56%49 to 85%50. Increased pain sensitivity, i.e. static mechanical hyperalgesia, 
was shown in RLS patients51. Interestingly, this increased pain sensitivity was significantly 
reduced after long-term (1 year) but not short-term levodopa treatment. However, pain 
sensitivity is also associated with poor sleep and depression52 and slow wave sleep 
deprivation53, all factors present to a certain degree in RLS. In addition, a study with 
[11C]diprenorphine PET found no difference of opioid binding between RLS subjects and 
controls, but within the group of RLS subjects opioid receptor binding correlated with RLS 
severity and questionnaire-based pain scores54. Overall, RLS responds to opioidergic agents 
and it is associated with painful medical conditions. Similar to the dopamine system a 
specific biomarker for an altered endogenous opiate system in RLS has not been identified.  
The involvement of the spinal cord in the pathophysiology of RLS is based on the fact that 
sensory and motor symptoms are bilateral and segmentally localized in most cases. Possibly 
either a sensory signal from the periphery to the sensory cortex is affected at the level of the 
spinal cord or the abnormal input itself is generated at that level. There are several case 
reports describing a new onset of RLS in close temporal association with spinal pathologies 
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such as lumbosacral radiculopathy55, borrelia-induced myelitis56, transverse myelitis57, 
vascular injury of the spinal cord58, traumatic lesions or cervical spondylotic myelopathy59. 
Interestingly, most of them responded to dopaminergic treatment56-58. After spinal anesthesia 
9% of 161 patients developed transient new onset RLS60 although this could not be 
confirmed in an independent study61. Given the high prevalence of RLS the scarcity of the 
case reports does not argue convincingly in favour of a spinal generator of sensory RLS 
symptoms. Even in “pure” spinal pathologies such as syringomyelia or syringobulbia where 
62% of unselected patients showed PLM none of them had symptoms of RLS62.The 
evidence for a role of spinal mechanisms is stronger for PLMS than RLS. In particular, even 
in completely paraplegic patients PLMS have been observed63-65, strongly suggesting a 
spinal origin of PLMS. Interestingly, the known lower occurrence of PLMS during rapid eye 
movement (REM) sleep is maintained in patients with spinal pathologies and only abolished 
in patients with complete spinal cord transsections63,64. PLMS have been likened to the 
Babinski sign66, which in healthy persons is absent during wake and REM-sleep but can be 
elicited during non-REM (NREM)-sleep67. More recently, it has been shown that the elicited 
flexor reflex and especially its late components are disinhibited in idiopathic RLS patients 
compared to controls during sleep and wakefulness68, which has been confirmed in uremic 
patients69. Taken together, there is evidence of a spinal hyperexcitability, which, however, 
might be more specific to PLMD as opposed to RLS. Whether this phenomenon is 
specifically located at the spinal cord level or reflects a loss of supraspinal inhibitory 
influences has not yet been resolved. 
Epidemiological studies have shown a markedly higher prevalence of RLS in women30,70 and 
this increased risk for RLS in females has been related to the number of pregnancies70. 
Prospective71, concurrent72 or retrospective assessment73 of RLS occurrence during 
pregnancy suggests that around 25% of females will experience RLS symptoms, with the 
highest prevalence during the last trimester. Hormonal changes during pregnancy are 
primarily increases in plasma levels of estrogens, progesteron and prolactin, and Ekbom8 
favoured a hormonal hypothesis regarding the incidence of RLS in pregnancy. While iron and 
folate requirements during pregnancy are increased and may play a role in the etiology of 
RLS71 there is, however, a recent study74 that followed pregnant women with and without 
RLS from the 35th week of gestation to approximately 12 weeks postpartum, and found 
markedly elevated estradiol levels in pregnant women with RLS during late-term pregnancy 
but not after delivery when subjects were symptom-free. We have explored the hormonal 
hypothesis of RLS by assessing the prevalence of RLS symptoms in a group of transsexual 
patients treated with either testosterone or estrogens with the hypothesis that male-to-female 
transsexual subjects treated with estrogens would report a higher prevalence of RLS 
symptoms than female-to-male transsexuals treated with testosterone (see CHAPTER IV). 
Peripheral neuropathy has been implicated as a cause for secondary RLS but the 
relationship with RLS seems to be complex75. It is thought that at the basic perceptual level 
sensory stimuli are distorted, possibly leading to a hypersensitization of the sensory pathway 
that may induce a circulus vitiosus maintaining restless legs symptoms. Although a greater 
percentage of RLS patients than previously expected may show subtle abnormalities when 
examined using electrophysiological or other sophisticated techniques it is also obvious that 
these abnormalities are not a necessary precondition for the development of RLS76,77,50. And 
although the prevalence of RLS in patients with neuropathy may be higher than expected in 
the general population, the majority of patients even with severe neuropathy will not develop 
RLS78,79. Whether neuropathy is a sufficient cause in selected patients to trigger or maintain 
RLS is still open to research.  
Ekbom himself decidedly favoured a vascular pathogenesis of RLS predominantly based on 
the good therapeutic results obtained by the use of two vasodilatative agents (carbachol and 
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tolazoline) in 23 out of 29 patients8. This is reminiscent of the clonidine treatment which has 
been found to be effective in two double-blind studies in idiopathic80 and uremic RLS81. 
However, in two large studies with 1566 primary care patients in the UK82 and 2404 subjects 
in the US83 the presence of RLS symptoms was unrelated to the venous reflux or venous 
obstruction determined by duplex ultrasonography. Like peripheral neuropathy, vascular 
disturbances can be caused by a multitude of common factors but they also have wide-
ranging consequences including peripheral nerve damage. The vascular hypothesis has 
recently received new scientific interest due to the newly emerging association of RLS and 
PLMS to heart disease, hypertension and stroke although the exact nature of the relationship 
is unclear at present84. 
In the idiopathic form of RLS a positive family history is often reported and large pedigrees 
with familial RLS suggest that the disorder follows a pattern of autosomal dominant 
inheritance with a high degree of penetrance85. Linkage and association studies have 
identified several loci (on chromosomes 12q, 14q, 9p, 2q, 16p, and 20p) for RLS but no 
disease-causing gene has been found as yet85. Genome-wide association studies have 
recently identified polymorphisms in three genes with no obvious relationship to dopamine 
that account for 70% of the population risk for RLS86,87 (see CHAPTER V). A single variant in 
the BTBD9 gene on chromosome 6 contributes to 50% of the population risk. Although the 
functions of BTBD9 remain uncertain, its biological plausibility is evidenced by its dose-
dependent relationship to periodic limb movements of sleep, decrements in iron stores, and 
ethnic differences in RLS prevalence.  
 
Treatment of RLS 
RLS tends to be a lifelong disorder. There exist many forms regarding the clinical course of 
the disease, the severity and circadian expression of symptoms as well as associated 
features, which makes it necessary to tailor RLS therapy to the individual patient. Also, in the 
idiopathic form, all treatment options are symptomatic and may be necessary for years or 
even decades. Thus, loss of effectiveness, side effects and augmentation are often 
encountered with long-term treatment of RLS. Because of the limited disease-specific 
knowledge current treatment strategies are not curative, but nevertheless may produce an 
effective and lasting relief of symptoms. Although clinically based treatment has focused on 
levodopa, opioids and benzodiazepines for a long time, evidence-based and clinical 
guidelines identify dopamine agonists as a first line treatment for daily restless legs 
symptoms. 
The severity of RLS can differ widely between subjects and is distinguished by such features 
as frequency and intensity of sensorimotor symptoms, the timing of symptoms during the 24 
h day and the association with insomnia. Insomnia might be secondary to RLS, constitute a 
concomitant disorder that needs specific treatment or may even be caused by the 
substances used to treat RLS (e.g. levodopa or dopamine agonists88). 
There are guidelines for the treatment of RLS, in particular the most thorough and evidence-
based review and guideline by the Restless Legs Syndrome Task Force of the Standards of 
Practice Committee of the American Academy of Sleep Medicine (AASM)42,89. The latest 
guidelines were published in 2008 and are based on studies that have been published until 
December 200690. A recent clinical guideline from the Medical Advisory Board of the 
Restless Legs Syndrome Foundation has been the very first RLS specialists’ consensus 
approach to a clinical algorithm for the treatment of RLS91. In this guideline the clinically 
useful distinction between intermittent, daily, and refractory RLS is made and different 
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treatment strategies are recommended. In addition, the guidelines recommend that (i) non-
pharmacological approaches are to be considered in every RLS patient, (ii) levodopa 
constitutes a treatment option for intermittent but not daily or refractory RLS, (iii) high potency 
opioids are reserved for severe refractory RLS, and (iv) dopamine agonists are the first line 
treatment. Non-pharmacological options that should be considered include recommending of 
mental alerting activities at times of restless legs symptoms. Cessation of alcohol, nicotine 
and caffeine intake could be tried and medications taken by the patient should be critically 
evaluated since several substances may induce or aggravate RLS. These include dopamine 
antagonists but also certain antidepressants. Iron status should be considered in every 
patient. 
Today, the established pharmacological options for RLS include levodopa, the dopamine 
agonists ropinirole, pramipexole, cabergoline, and pergolide and gabapentin90. Several other 
drugs such as rotigotine, bromocriptine, oxycodone, carbamazepine, valproic acid and 
clonidine have been shown to be efficacious in some studies92. The efficiency of oral iron on 
RLS symptoms depends on the iron status of the subject and the use of intravenous iron is 
considered investigational at present90 .  
As a disorder RLS is unique in the sense that it responds to both dopaminergic and 
opiodergic agents which are the two main systems thought to play a crucial role in the 
physiological response to a placebo93. Indeed, in recent treatment trials, a large and lasting 
placebo effect has been observed with up to 50% of RLS patients reporting a substantial and 
clinically significant improvement of RLS symptoms during placebo treatment94-96. To 
elucidate this effect, we have conducted a systematic review and meta-analysis97 that 
quantified the magnitude of the placebo effect in RLS treatment studies, combining results 
from studies conducted during the past 25 years (see CHAPTER III).  We have also explored 
whether the placebo effect differed between the various outcome modalities assessed in 
RLS treatment trials such as RLS severity, PLMS index, subjective and objective 
assessment of sleep and daytime functioning. Our main findings were a placebo effect that 
was large for the RLS severity measures, moderate for daytime functioning, small to 
moderate for subjective and objective sleep parameters, and absent for PLMS and sleep 
efficiency. This has led us to propose that RLS is a model disease to study the mechanisms 
of the placebo response. 
 
 
In the following, four studies addressing open questions in the diagnosis, treatment, and 
pathophysiology of RLS are presented. In particular, these explore cognitive functioning in 
RLS (Chapter II), the placebo response in RLS treatment studies (Chapter III), the 
prevalence of RLS in transsexual patients (Chapter IV), and the first genome-wide 
association study in RLS (Chapter V). The findings of these studies are discussed in the 
respective chapters and in relation to more recent evidence in the final discussion (Chapter 
VI). 
 
 
 
 
 7 
Introduction 
References 
1. Allen, R.P. et al. Restless legs syndrome: diagnostic criteria, special considerations, and 
epidemiology. A report from the restless legs syndrome diagnosis and epidemiology 
workshop at the National Institutes of Health. Sleep Med. 4, 101-119 (2003). 
2. Garcia-Borreguero, D., Egatz, R., Winkelmann, J. & Berger, K. Epidemiology of restless 
legs syndrome: the current status. Sleep Med. Rev. 10, 153-167 (2006). 
3. Willis, T. De Animae Brutorum.  (Wells and Scott: London, 1672). 
4. Willis, T. The London practice of physick: or the whole practical part of physick contained in the works of Dr. Willis. Faithfully made English, and printed together for the publick good.  (Basset and Crooke: London, 1685). 
5. Wittmaack, T. Pathologie und Therapie der Sensibiliät-Neurosen.  (E. Schäfer: Leipzig, 
1861). 
6. Allison, F. Obscure pains in the chest, back or limbs. Can. Med. Assoc. J. 48, 36-38 
(1943). 
7. Ekbom, K. Asthenia crurum paraesthetica ('irritable legs'). New syndrome consisting of 
weakness, sensation of cold and nocturnal paresthesia in legs, responding to certain 
extent to treatment with Priscol and Doryl; note on paresthesia in general. Acta Med.Scand. 118, 197-209 (1944). 
8. Ekbom, K.A. Restless legs: clinical study of hitherto overlooked disease in legs 
characterized by peculiar paresthesia ('anxietas tibiarum'), pain and weakness and 
occuring in two main forms, asthenia crurum paresthetica and asthenia crurum dolorosa; 
short review of paresthesias in general. Acta Med. Scand. 158, 1-123 (1945). 
9. American Academy of Sleep Medicine The international classification of sleep disorders: diagnostic and coding manual.  (American Academy of Sleep Medicine: Westchester, 
Illinois, 2005). 
10. Akpinar, S. Treatment of restless legs syndrome with levodopa plus benserazide. Arch. Neurol. 39, 739 (1982). 
11. Walters, A.S. Toward a better definition of the restless legs syndrome. The International 
Restless Legs Syndrome Study Group. Mov. Disord. 10, 634-642 (1995). 
12. Wetter, T.C., Eisensehr, I. & Trenkwalder, C. Functional neuroimaging studies in restless 
legs syndrome. Sleep Med. 5, 401-406 (2004). 
13. Trenkwalder, C. & Paulus, W. Why do restless legs occur at rest?--pathophysiology of 
neuronal structures in RLS. Neurophysiology of RLS (part 2). Clin. Neurophysiol. 115, 
1975-1988 (2004). 
14. Allen, R.P. & Earley, C.J. Restless legs syndrome: a review of clinical and 
pathophysiologic features. J. Clin. Neurophysiol. 18, 128-147 (2001). 
15. Walters, A.S. et al. A questionnaire study of 138 patients with restless legs syndrome: 
the 'Night-Walkers' survey. Neurology 46, 92-95 (1996). 
16. Ondo, W. & Jankovic, J. Restless legs syndrome: clinicoetiologic correlates. Neurology 
47, 1435-1441 (1996). 
17. Michaud, M., Paquet, J., Lavigne, G. & Desautels, A. Sleep laboratory diagnosis of 
restless legs syndrome. Eur. Neurol. 48, 108-113 (2002). 
18. Stiasny-Kolster, K., Kohnen, R., Möller, J., Trenkwalder, C. & Oertel, W. Validation of the 
"L-DOPA test" for diagnosis of restless legs syndrome. Mov.Disord. 21, 1333-1339 
(2006). 
19. Nordlander, N. Therapy in restless legs. Acta Med.Scand. 145, 453-457 (1953). 
20. O'Keeffe, S., Gavin, K. & Lavan, J. Iron status and restless legs syndrome in the elderly. Age Ageing 23, 200-203 (1994). 
21. Collado-Seidel, V. et al. Clinical and biochemical findings in uremic patients with and 
without restless legs syndrome. Am.J.Kidney Dis. 31, 324-328 (1998). 
22. Wang, D. & Teichtahl, H. Opioids, sleep architecture and sleep-disordered breathing. Sleep Med. Rev. 11, 35-46 (2007). 
23. Walters, A. et al. Long-term follow-up on restless legs syndrome patients treated with 
opioids. Mov.Disord. 16, 1105-1109 (2001). 
24. Gemignani, F. et al. Restless legs syndrome and polyneuropathy. Mov. Disord. 21, 1254-
1257 (2006). 
 8 
Introduction 
25. Walters, A.S., Wagner, M. & Hening, W.A. Periodic limb movements as the initial 
manifestation of restless legs syndrome triggered by lumbosacral radiculopathy. Sleep 
19, 825-826 (1996). 
26. Walters, A.S., Hening, W., Rubinstein, M. & Chokroverty, S. A clinical and 
polysomnographic comparison of neuroleptic-induced akathisia and the idiopathic 
restless legs syndrome. Sleep 14, 339-345 (1991). 
27. Rottach, K.G. et al. Restless legs syndrome as side effect of second generation 
antidepressants. J. Psychiatr. Res. 43, 70-75 (2008). 
28. Hoque, R. & Chesson, A.L. Pharmacologically induced/exacerbated restless legs 
syndrome, periodic limb movements of sleep, and REM behavior disorder/REM sleep 
without atonia: literature review, qualitative scoring, and comparative analysis. J. Clin. Sleep Med. 6, 79-83 (2010). 
29. Abetz, L. et al. Evaluating the quality of life of patients with restless legs syndrome. Clin. Ther. 26, 925-935 (2004). 
30. Allen, R.P. et al. Restless legs syndrome prevalence and impact: REST general 
population study. Arch. Intern. Med. 165, 1286-1292 (2005). 
31. Happe, S. et al. Assessing health-related quality of life in patients with restless legs 
syndrome. Sleep Med. 10, 295-305 (2009). 
32. Fulda, S. & Wetter, T.C. Is daytime sleepiness a neglected problem in patients with 
restless legs syndrome? Mov. Disord. 22, S409-413 (2007). 
33. Saletu, B. et al. EEG mapping, psychometric, and polysomnographic studies in restless 
legs syndrome (RLS) and periodic limb movement disorder (PLMD) patients as 
compared with normal controls. Sleep Med. 3, S35-42 (2002). 
34. Pearson, V.E. et al. Cognitive deficits associated with restless legs syndrome (RLS). Sleep Med. 7, 25-30 (2006). 
35. Driver-Dunckley, E. et al. No evidence for cognitive dysfunction or depression in patients 
with mild restless legs syndrome. Mov. Disord. 24, 1843-1847 (2009). 
36. Celle, S. et al. Prevalence and clinical correlates of restless legs syndrome in an elderly 
French population: the synapse study. J. Gerontol. A Biol. Sci. Med. Sci. 65, 167-173 
(2010). 
37. Barrière, G., Cazalets, J., Bioulac, B., Tison, F. & Ghorayeb, I. The restless legs 
syndrome. Prog. Neurobiol. 77, 139-165 (2005). 
38. Allen, R.P. & Earley, C.J. The role of iron in restless legs syndrome. Mov. Disord. 22, 
S440-S448 (2007). 
39. Earley, C.J. et al. Abnormalities in CSF concentrations of ferritin and transferrin in 
restless legs syndrome. Neurology 54, 1698-1700 (2000). 
40. Allen, R., Barker, P., Wehrl, F., Song, H. & Earley, C. MRI measurement of brain iron in 
patients with restless legs syndrome. Neurology 56, 263-265 (2001). 
41. Connor, J. et al. Neuropathological examination suggests impaired brain iron acquisition 
in restless legs syndrome. Neurology 61, 304-309 (2003). 
42. Hening, W.A., Allen, R.P., Earley, C.J., Picchietti, D.L. & Silber, M.H. An update on the 
dopaminergic treatment of restless legs syndrome and periodic limb movement disorder. Sleep 27, 560-583 (2004). 
43. Kraus, T., Schuld, A. & Pollmacher, T. Periodic leg movements in sleep and restless legs 
syndrome probably caused by olanzapine [5]. J. Clin. Psychopharmacol. 19, 478-479 
(1999). 
44. Winkelmann, Schadrack, Wetter, Zieglgänsberger & Trenkwalder Opioid and dopamine 
antagonist drug challenges in untreated restless legs syndrome patients. Sleep Med. 2, 
57-61 (2001). 
45. Garcia-Borreguero, D., Larrosa, O. & de la Llave, Y. Circadian aspects in the 
pathophysiology of the restless legs syndrome. Sleep Med. 3, S17-21 (2002). 
46. Kaplan, P.W., Allen, R.P., Buchholz, D.W. & Walters, J.K. A double-blind, placebo-
controlled study of the treatment of periodic limb movements in sleep using 
carbidopa/levodopa and propoxyphene. Sleep 16, 717-723 (1993). 
47. Walters, A.S. et al. Successful treatment of the idiopathic restless legs syndrome in a 
randomized double-blind trial of oxycodone versus placebo. Sleep 16, 327-332 (1993). 
48. Walters, A.S. Review of receptor agonist and antagonist studies relevant to the opiate 
system in restless legs syndrome. Sleep Med. 3, 301-304 (2002). 
 9 
Introduction 
49. Bassetti, C.L., Mauerhofer, D., Gugger, M., Mathis, J. & Hess, C.W. Restless legs 
syndrome: a clinical study of 55 patients. Eur. Neurol. 45, 67-74 (2001). 
50. Winkelmann, J. et al. Clinical characteristics and frequency of the hereditary restless legs 
syndrome in a population of 300 patients. Sleep 23, 597-602 (2000). 
51. Stiasny-Kolster, K., Magerl, W., Oertel, W.H., Möller, J.C. & Treede, R. Static mechanical 
hyperalgesia without dynamic tactile allodynia in patients with restless legs syndrome. Brain 127, 773-782 (2004). 
52. Chiu, Y.H. et al. Poor sleep and depression are independently associated with a reduced 
pain threshold. Results of a population based study. Pain 115, 316-321 (2005). 
53. Onen, S.H., Alloui, A., Gross, A., Eschallier, A. & Dubray, C. The effects of total sleep 
deprivation, selective sleep interruption and sleep recovery on pain tolerance thresholds 
in healthy subjects. J. Sleep Res. 10, 35-42 (2001). 
54. von Spiczak, S. et al. The role of opioids in restless legs syndrome: an 
[11C]diprenorphine PET study. Brain 128, 906-917 (2005). 
55. Walters, A.S., Wagner, M. & Hening, W.A. Periodic limb movements as the initial 
manifestation of restless legs syndrome triggered by lumbosacral radiculopathy. Sleep 
19, 825-826 (1996). 
56. Hemmer, B., Riemann, D., Glocker, F.X., Lücking, C.H. & Deuschl, G. Restless legs 
syndrome after a borrelia-induced myelitis. Mov. Disord. 10, 521-522 (1995). 
57. Brown, L.K., Heffner, J.E. & Obbens, E.A. Transverse myelitis associated with restless 
legs syndrome and periodic movements of sleep responsive to an oral dopaminergic 
agent but not to intrathecal baclofen. Sleep 23, 591-594 (2000). 
58. Tings, T., Baier, P.C., Paulus, W. & Trenkwalder, C. Restless Legs Syndrome induced 
by impairment of sensory spinal pathways. J. Neurol. 250, 499-500 (2003). 
59. Hartmann, M., Pfister, R. & Pfadenhauer, K. Restless legs syndrome associated with 
spinal cord lesions. J. Neurol. Neurosurg. Psychiatr. 66, 688-689 (1999). 
60. Högl, B., Frauscher, B., Seppi, K., Ulmer, H. & Poewe, W. Transient restless legs 
syndrome after spinal anesthesia: a prospective study. Neurology 59, 1705-1707 (2002). 
61. Crozier, T.A., Karimdadian, D. & Happe, S. Restless legs syndrome and spinal 
anesthesia. N. Engl. J. Med. 359, 2294-2296 (2008). 
62. Nogués, M. et al. Periodic limb movements in syringomyelia and syringobulbia. Mov. Disord. 15, 113-119 (2000). 
63. Dickel, M.J., Renfrow, S.D., Moore, P.T. & Berry, R.B. Rapid eye movement sleep 
periodic leg movements in patients with spinal cord injury. Sleep 17, 733-738 (1994). 
64. Yokota, T., Hirose, K., Tanabe, H. & Tsukagoshi, H. Sleep-related periodic leg 
movements (nocturnal myoclonus) due to spinal cord lesion. J. Neurol. Sci. 104, 13-18 
(1991). 
65. de Mello, M.T., Lauro, F.A., Silva, A.C. & Tufik, S. Incidence of periodic leg movements 
and of the restless legs syndrome during sleep following acute physical activity in spinal 
cord injury subjects. Spinal Cord 34, 294-296 (1996). 
66. Smith, R.C. Relationship of periodic movements in sleep (nocturnal myoclonus) and the 
Babinski sign. Sleep 8, 239-243 (1985). 
67. Fujiki, A., Shimizu, A., Yamada, Y., Yamamoto, J. & Kaneko, Z. The Babinski reflex 
during sleep and wakefulness. Electroencephalogr. Clin. Neurophysiol. 31, 610-613 
(1971). 
68. Bara-Jimenez, W., Aksu, M., Graham, B., Sato, S. & Hallett, M. Periodic limb movements 
in sleep: state-dependent excitability of the spinal flexor reflex. Neurology 54, 1609-1616 
(2000). 
69. Aksu, M. & Bara-Jimenez, W. State dependent excitability changes of spinal flexor reflex 
in patients with restless legs syndrome secondary to chronic renal failure. Sleep Med. 3, 
427-430 (2002). 
70. Berger, K., Luedemann, J., Trenkwalder, C., John, U. & Kessler, C. Sex and the risk of 
restless legs syndrome in the general population. Arch. Intern. Med. 164, 196-202 
(2004). 
71. Lee, K.A., Zaffke, M.E. & Baratte-Beebe, K. Restless legs syndrome and sleep 
disturbance during pregnancy: the role of folate and iron. J. Womens Health Gend. Based Med. 10, 335-341 (2001). 
 10 
Introduction 
 11 
72. Suzuki, K. et al. The prevalence of restless legs syndrome among pregnant women in 
Japan and the relationship between restless legs syndrome and sleep problems. Sleep 
26, 673-677 (2003). 
73. Manconi, M. et al. Restless legs syndrome and pregnancy. Neurology 63, 1065-1069 
(2004). 
74. Dzaja, A., Wehrle, R., Lancel, M. & Pollmächer, T. Elevated estradiol plasma levels in 
women with restless legs during pregnancy. Sleep 32, 169-174 (2009). 
75. Pourfar, M. & Feigin, A. The numb and the restless: Peripheral neuropathy and RLS. Neurology 72, 950-951 (2009). 
76. Polydefkis, M. et al. Subclinical sensory neuropathy in late-onset restless legs syndrome. Neurology 55, 1115-1121 (2000). 
77. Machtey, I. Epidemiology of restless legs syndrome. Arch. Intern. Med. 161, 483-484 
(2001). 
78. Rutkove, S.B., Matheson, J.K. & Logigian, E.L. Restless legs syndrome in patients with 
polyneuropathy. Muscle Nerve 19, 670-672 (1996). 
79. Hattan, E., Chalk, C. & Postuma, R.B. Is there a higher risk of restless legs syndrome in 
peripheral neuropathy? Neurology 72, 955-960 (2009). 
80. Wagner, M.L. et al. Randomized, double-blind, placebo-controlled study of clonidine in 
restless legs syndrome. Sleep 19, 52-58 (1996). 
81. Ausserwinkler, M. & Schmidt, P. Erfolgreiche Behandlung des "restless legs"-Syndroms 
bei chronischer Niereninsuffizienz mit Clonidin. Schweiz. Med. Wochenschr. 119, 184-
186 (1989). 
82. Bradbury, A. et al. The relationship between lower limb symptoms and superficial and 
deep venous reflux on duplex ultrasonography: The Edinburgh Vein Study. J. Vasc. Surg. 32, 921-931 (2000). 
83. Langer, R.D. et al. Relationships between symptoms and venous disease: the San Diego 
population study. Arch. Intern. Med. 165, 1420-1424 (2005). 
84. Walters, A.S. & Rye, D.B. Review of the relationship of restless legs syndrome and 
periodic limb movements in sleep to hypertension, heart disease, and stroke. Sleep 32, 
589-597 (2009). 
85. Winkelmann, J. et al. Genetics of restless legs syndrome (RLS): State-of-the-art and 
future directions. Mov. Disord. 22, S449-458 (2007). 
86. Winkelmann, J. et al. Genome-wide association study of restless legs syndrome 
identifies common variants in three genomic regions. Nat. Genet. 39, 1000-1006 (2007). 
87. Stefansson, H. et al. A genetic risk factor for periodic limb movements in sleep. N. Engl. J. Med. 357, 639-647 (2007). 
88. Fulda, S. & Wetter, T.C. Dopamine agonists for the treatment of restless legs syndrome. Expert Opin. Pharmacother. 6, 2655-2666 (2005). 
89. Littner, M.R. et al. Practice parameters for the dopaminergic treatment of restless legs 
syndrome and periodic limb movement disorder. Sleep 27, 557-559 (2004). 
90. Trenkwalder, C. et al. Treatment of restless legs syndrome: an evidence-based review 
and implications for clinical practice. Mov. Disord. 23, 2267-2302 (2008). 
91. Silber, M.H. et al. An algorithm for the management of restless legs syndrome. Mayo Clin. Proc. 79, 916-922 (2004). 
92. Fulda, S. & Wetter, T.C. Emerging drugs for restless legs syndrome. Expert Opin. Emerg. Drugs 10, 537-552 (2005). 
93. Colloca, L., Lopiano, L., Benedetti, F. & Lanotte, M. Placebo response in conditions other 
than pain. Semin. Pain Med. 3, 43-47 (2005). 
94. Allen, R. et al. Ropinirole decreases periodic leg movements and improves sleep 
parameters in patients with restless legs syndrome. Sleep 27, 907-914 (2004). 
95. Trenkwalder, C. et al. Ropinirole in the treatment of restless legs syndrome: results from 
the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 
European countries. J. Neurol. Neurosurg. Psychiatr. 75, 92-97 (2004). 
96. Walters, A. et al. Ropinirole is effective in the treatment of restless legs syndrome. 
TREAT RLS 2: a 12-week, double-blind, randomized, parallel-group, placebo-controlled 
study. Mov.Disord. 19, 1414-1423 (2004). 
97. Fulda, S. & Wetter, T.C. Where dopamine meets opioids: a meta-analysis of the placebo 
effect in restless legs syndrome treatment studies. Brain 131, 902-917 (2008). 
 
Cognitive functioning in RLS 
 
 12  12 
II. Short-term attention and verbal fluency is decreased in 
restless legs syndrome patients 
 
 
This is a pre-copy-editing, author-produced PDF of an article accepted for publication in 
Movement Disorders following peer review. The definitive publisher-authenticated version 
[Short-term attention and verbal fluency is decreased in restless legs syndrome patients. 
Stephany Fulda, Marie E. Beitinger, Simone Reppermund, Juliane Winkelmann, Thomas C. 
Wetter. Movement Disorders 2010; DOI 10.1002/mds.23353] is available at: 
 www3.interscience.wiley.com  
 
Abstract 
Restless legs syndrome (RLS) is a frequent sleep-related movement disorder with disturbed 
sleep and quality of life. RLS patients complain about increased daytime sleepiness but there 
are only few and inconsistent reports about cognitive functioning in this group. We compared 
cognitive performance of 23 unmedicated RLS patients to that of 23 healthy controls 
matched individually for age, gender, and educational level. Cognitive tasks were chosen to 
assess short term attention, working memory, learning and memory, verbal fluency, and 
executive functioning. RLS patients performed worse than controls in the area of attention 
and verbal fluency and performance in these tasks was associated with RLS severity, sleep 
quality, depression scores, and iron status. There was no difference for working memory, 
memory, learning, cognitive flexibility, and abstract reasoning. We conclude that there is 
evidence for deficits in short-term attention and verbal fluency in RLS patients.  
 
 
Introduction  
The restless legs syndrome (RLS) is a neurological disorder characterized by the urge to 
move the extremities associated with paraesthesias which are partially or totally relieved by 
movement, a worsening of symptoms at rest and in the evening or at night and, as a 
consequence, sleep disturbances1,2. RLS is a frequent disorder and epidemiological studies 
show a rather consistent prevalence of 3 to 10% for lifetime occurrence of RLS in European 
and North-American populations3. Commonly distinguished within the population exhibiting 
RLS symptoms are so-called RLS sufferers in whom RLS symptoms occur on a frequent 
basis (e.g. at least two times a week) and with at least moderate distress4,5. Indeed, several 
studies have shown that RLS is associated with a significantly reduced quality of life, and 
within the different domains of quality of life the areas “energy / sleepiness” and 
“performance” are particularly impaired5-8. Independent investigations in different populations 
such as the general population or sleep lab populations revealed that about one third of RLS 
                                                 
 Fulda S, Beitinger ME, Reppermund S, Winkelmann J, Wetter TC. Short-term attention and verbal 
fluency is decreased in restless legs syndrome patients. Movement Disorders 2010; 25: 2641-2648. 
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subjects perceive themselves as being excessively sleepy during the daytime (reviewed in9). 
Considerably less is known about performance deficits in subjects with RLS. So far, there 
have been four published studies on cognitive functioning in RLS patients10-13, although 
several other research groups, including ours, have reported preliminary data at scientific 
meetings14-17. Taken together, these studies showed cognitive deficits in the area of attention 
and executive functioning in subjects with clinically significant RLS10,11,13 but not in subjects 
with mild RLS12. The aim of the present study was to further characterize cognitive deficits in 
unmedicated RLS subjects by assessing a broad range of cognitive functions and to increase 
the specificity of findings by carefully matching healthy controls from a general population 
sample on a one-to-one basis according to age, gender, and educational level. In addition, 
we explored potential determinants of cognitive deficits in this patient group.  
 
Methods 
Subjects 
We included consecutive unmedicated subjects with RLS visiting the RLS outpatient clinic at 
the Max Planck Institute of Psychiatry, Munich. RLS was unequivocally diagnosed according 
to established criteria1 by an experienced RLS expert. Polysomnography was conducted in 
seven patients according to clinical need. Exclusion criteria were any psychiatric disorder, 
any neurological or brain disorder or other sleep disorder suspected to interfere with the 
cognitive performance, and any severe and untreated medical conditions. Patients had to be 
free of any RLS medication, hypnotics or narcotics for at least two weeks; stable medication 
intake for chronic conditions such as hypertension were allowed. 
Control subjects were recruited from a general population study in which participants were 
randomly drawn from community registries of all residents aged between 18 and 75 years 
living in the metropolitan area of Munich. Inclusion criteria for the general population study 
were (1) European descent, (2) no professional psychological help-seeking at any time, and 
(3) no severe somatic disorder. Subjects were rated in a face-to-face interview using a 
computer-assisted diagnostic interview (modified version of the Munich-Composite-
International-Diagnostic Interview, DIA-X/M-CIDI18). All persons with a lifetime history of 
alcohol dependence, drug abuse or dependence, possible psychotic disorder, mood disorder, 
anxiety disorder including obsessive-compulsive disorder and post-traumatic stress disorder, 
somatoform disorder, dissociative disorder not otherwise specified, and eating disorder 
according to the M-CIDI interview were excluded. Subjects older than 65 years were 
additionally tested using the Mini Mental State Examination (MMSE), and were excluded 
from further procedures if having a score of less than 27. Controls were selected from this 
sample according to age (± 3 years), gender, and educational level to match individual RLS 
subjects. The study was approved by the local ethics committee and all participants gave 
informed written consent.  
 
Procedure 
All subjects completed the Pittsburgh Sleep Quality Index (PSQI19), the Epworth Sleepiness 
Scale (ESS20), the symptom check list SCL-90-R21,22, the Beck Depression Inventory (BDI23), 
and the state-trait anxiety inventory (STAI24). Subjects with RLS also completed the 
international RLS study group scale (IRLS25,26).  
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Table 1. Description of neuropsychological tasks 
 
Name (Short name)  Cognitive function / Description 
Attention   
D2 Cancellation test (d2)27 
[Aufmerksamkeits-Belastungstest d2] 
Selective visual attention 
Paper-and-pencil speed cancellation test where subjects are asked to search for the 
target stimulus among non-targets. The performance score is calculated as the 
number of correctly canceled items within 4:40 minutes. 
Trail-Making Test (ZVT)28 
[Zahlen-Verbindungs-Test] Focused attention  Paper-and-pencil test similar to the Trail-MakingTest A28. The subject has to connect 
as quickly as possible the numbers 1 to 90 which are arranged pseudo-randomly on a 
sheet of paper. Two matrices were administered (ZVT-A, ZVT-B), and the average 
time of both matrices was used as a measure of focused attention.  
Digit span forward 
Block span forward30 
Attention span 
From the revised German version of the Wechsler Memory Scale (WMS-R29). For the 
digit span the subject has to recall digit sequences of increasing length that are read 
out by the examiner. For the block span sequences of increasing lengths are tapped 
by the examiner and the participant has to tap the blocks in the same order. The 
number of correctly reproduced sequences is used as test score.  
Stroop test31,32 Selective attention  
The test consists of three sub-tasks where the subject is required to (i) read names of 
colors written in black ink, (ii) name the color of squares printed in different colors, and 
(iii) name the color of color name words printed in both congruent colors (i.e. “green” 
printed in green ink) and incongruent colors (i.e. “green” printed in red ink). The 
difference between the (log-transformed) time for color naming of squares and the 
(log-transformed) time for color naming of the ink of a color word is taken as a 
measure of the Stroop effect.  
Memory  
Digit span backward 
Block span backward30 
Working memory 
The subject is confronted with sequences of increasing lengths and has to reproduce 
them in the backward order. The number of sequences correctly reproduced backward 
is used as the test score. 
Munich Verbal Memory Test 
(MVG)33 
[Münchner Verbaler Gedächtnistest] 
Learning and memory 
German version of the California Verbal Learning test (CVLT33). Sixteen items are 
presented once and according to a selective reminding procedure for 4 consecutive 
trials with immediate recall after each. Following the presentation and immediate recall 
of another 16-item interference list, free and category cued recall trials are presented 
after short and long delays (45 - 60 minutes). Scores used in the present analysis are 
immediate recall from trial 1, learning performance represented as recall from the last 
trial 5, short-term and long-term free recall.  
Executive functioning  
Regensburg Verbal Fluency 
Test (RWT)35 
- Subtasks 1 and 2 
 [Regensburger Wortflüssigkeitstest] 
Verbal fluency 
The test asks the subject to name as many words as possible from a category within 2 
minutes. This category is phonemic (e.g. words that begin with the letter “p”) or 
semantic (e.g. “animals” or “fruits”).  
Regensburg Verbal Fluency 
Test (RWT)35 
- Subtasks 3 and 4 
 
Cognitive flexibility and set shifting 
Two further subtasks of the RWT ask the subject again to name as many words as 
possible, but this time words have to come from alternating categories (e.g. letters “a” 
and “t” or categories “sport” and “clothing”). For each task, the total number of correct 
words produced within 2 minutes was taken as a measure of cognitive flexibility. 
Raven's Progressive Matrices 
(RPM)36,37 
Abstract reasoning 
RPM are multiple-choice tests of abstract reasoning, originally developed by Raven in 
1936387. The subject to whom five sets (A to E) of items are presented is asked to 
identify, among several choices, the missing segment required to complete a larger 
pattern. Difficulty increases from sets A to E. For the present study, all subjects had 45 
minutes to complete all five sets, and the measured outcome was the number of 
correct choices per set and the total number of correct choices. 
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Neuropsychological Testing 
All subjects were tested in the morning for approximately 2 hours between 08:00 and 13:00 
hour and all RLS subjects were symptom-free at the time of testing. Cognitive tasks are 
described in Table 1 and were selected to assess a broad range of cognitive functions 
including short-term attention27-32, memory30,33,34, verbal fluency35, and executive functions35-38. 
In addition, all subjects completed a standard vocabulary test (Mehrfachwahlwortschatztest, 
MWT-B39) to compare overall pre-morbid intelligence.  
 
Performance Scores and Statistical Analysis 
For the statistical analysis of neuropsychological performance, raw performance scores were 
transformed to z-scores relative to German age- and/or gender-specific normative 
data27,28,30,31,33,35,36.  
Neuropsychological testing yielded a total of 16 z-scores for each subject. To control for 
overall error level these were grouped into six domains (attention, working memory, memory, 
verbal fluency, cognitive flexibility, and abstract reasoning) and multivariate analysis of 
variance (mANOVA) was employed for each domain to explore overall differences between 
RLS subjects and controls. Only significant multivariate effects were followed up by 
univariate ANOVAs. Because controls were matched individually to the respective RLS 
subject, the group factor (RLS vs. control) was implemented as a repeated-measures factor. 
 
           Table 2. Description of RLS subjects.  
 Mean ± SD (Range) n = 23 
IRLS 23.52 ± 7.40 (10 - 37) 
Age of onset, years (n = 22) 34.95 ± 15.90 (10 - 69) 
Age of onset ≤ 45 years (n, %) 16 (70%) 
Familial RLS (n, %) 6 (26%) 
Possibly familial RLS (n, %) 4 (17%) 
Sporadic RLS (n, %) 12 (52%) 
Family history unknown (n, %) 1 (4%) 
 Medication status before study*  
   De novo (n, %) 9 (39%) 
   De novo + L-dopa test (n, %) 7 (30%) 
   Dopaminergic medication (n, %) 6 (26%) 
   Other RLS medication (n, %) 1 (4%) 
 Ferritin (ng/ml) (n = 17)  116.47± 108.12 (8 - 457) 
Ferritin < 20 ng/ml (n, %) (n = 17) 4 (23%) 
Ferritin < 50 ng/ml (n, %) (n = 17) 7 (41%) 
IRLS = International RLS severity scale *All patients were medication-free for at least 14 days at the time of cognitive testing. 
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Data was missing from one control subject for Raven's Progressive Matrices and the 
respective patient-control pair was excluded from the analysis for this task. To standardize 
case-control differences across measures, Cohen's d, an effect size measure40, was 
computed for all variables and is listed in Table 2 for descriptive purposes. Conventionally, 
for Cohen's d an effect size of 0.2 to 0.3 is considered a “small” effect, around 0.5 a 
“medium” effect and 0.8 or larger, a “large” effect40. Differences between RLS patients and 
controls regarding demographic characteristics, sleep, and mood-related information were 
explored with paired t-tests and Chi2-tests as appropriate. Correlations and t-tests were used 
to assess age, RLS severity, subjective sleep duration, sleep quality, daytime sleepiness, 
and ferritin levels as potential determinants of cognitive dysfunction in RLS subjects.  
 
 
Table 3. Description of study participants.  
 RLS Control  
 Mean ± SD (Range) Mean ± SD (Range)  
 n = 23 n = 23 Test statistics, p 
Age, years 54.91 ± 12.17 (20 - 73) 54.70 ± 12.94 (19 - 73) t(df=22) = 0.69  p = 0.496 
Male/female (n) 9/14 9/14  
Vocabulary (MWT-B) 30.61 ± 4.38 (20 - 36) 31.83 ± 4.36 (19 - 37) t(df=22) = - 1.41  p = 0.172 
 Beck Depression Inventory  8.35 ± 6.23 (1 - 26) 
 2.61 ± 2.72 (0 - 9) 
 t(df=22) = 3.56 p = 0.002 
STAI-State 39.48 ± 9.44 (25 - 67) 36.43 ± 10.21 (24 - 56) t(df=22) = 0.99 p = 0.331 
STAI-Trait 37.56 ± 8.66 (26 - 57) 33.13 ± 7.19 (24 - 46) t(df=22) = 1.72 p = 0.099 
SCL-90R Global severity index 0.46 ± 0.29 (0.01 - 1.12) 0.16 ± 0.10 (0.02 - 0.33) t(df=22) = 4.46 p < 0.001 
SCL-90R Positive symptom distress index 1.45 ± 0.23 (1.00 - 1.79) 1.11 ± 0.20 (1.00 - 1.67) t(df=22) = 5.38 p < 0.001 
SCL-90R Positive symptom total 27.30 ± 16.39 (1.00 - 60.00) 13.30 ± 8.42 (2.00 - 29.00) t(df=22) = 3.58 p = 0.002 
 PSQI  10.91 ± 4.83 (2 - 20) 
 3.43 ± 1.93 (1 - 7) 
 t(df=22) = 6.52 p < 0.001 
PSQI > 5 (n, %)  18 (78%) 4 (17%) Chi2(df=1) = 14.72 p < 0.001 
Sleep duration, hours (PSQI) 5:30 ± 1:12 (3:30 - 7:30) 7:08 ± 0:47 (06:00 - 09:00) t(df=22) = -5.48 p < 0.001 
 ESS  9.65 ± 5.38 (0 - 17) 
 5.83 ± 2.95 (1 - 11) 
 t(df=22) = 3.63 p = 0.001 
ESS > 11 (n, %) 11 (48%) 0 (0%) Chi2(df=1) = 11.95 p < 0.001 
MWT-B = Mehrfachwahl-Wortschatztest; ESS = Epworth Sleepiness Scale; PSQI = Pittsburgh Sleep Quality Index; SCL-90R = Symptom Check List 90, revised; STAI = State-Trait Anxiety Inventory 
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Results 
A total of 27 RLS subjects participated in the study. From these four subjects were excluded: 
one subject because of a formerly undisclosed history of brain infarction, and three subjects 
(aged 70 to 79 years) because we were unable to locate matching control subjects. The final 
study group comprised 23 subjects with RLS (9 males, 14 females) aged 20 to 73 years (see 
Tables 2 and 3). The age of onset of RLS symptoms was between 10 and 69 years of age 
and was below the age of 45 in 16 of the patients (69%). More than half of the patients (n = 
16, 69%) had never been treated for RLS, although seven of these had a single L-dopa test 
to which all responded positive. Six RLS subjects had taken dopaminergic medication in the 
past, one subject had used gabapentin for several weeks. All were medication-free for at 
least 14 days before the study. Ferritin levels were available for 17 of the RLS subjects 
(74%) and were below 50 ng/ml for seven subjects (41%), four of which had levels below 20 
ng/ml (23%).  
Although none of the RLS subjects had a psychiatric disorder, self-report questionnaires 
revealed elevated depression scores (BDI) compared to the control group (Table 3). Self-
reported state anxiety did not differ between patients and controls, while there was a trend (p 
< 0.10) towards increased trait anxiety in RLS subjects. Also, overall psychological distress 
(SCL-90R), the number of self-reported symptoms and their intensity were increased in RLS 
subjects compared to controls. 
Sleep quality was significantly worse in RLS subjects and more RLS subjects showed PSQI 
values above the threshold of five (78% vs. 17%, Table 3). Self-reported sleep duration was 
significantly shorter in patients, and daytime sleepiness (ESS) was increased in the RLS 
group, with half of them (48%) showing increased daytime sleepiness (ESS > 11) while none 
of the control group did (Table 3). 
Multivariate analysis revealed that cognitive functioning differed between RLS subjects and 
controls in the area of attention and verbal fluency (Table 4). There was no overall difference 
between the groups in tasks assessing working memory, learning and memory, cognitive 
flexibility, and abstract reasoning. Within the attention domain, RLS subjects performed 
worse than controls in the d2-cancellation task and the Stroop task, which evaluate short-
term selective visual attention and vulnerability to interference. In the verbal fluency domain, 
both letter and category fluency were reduced in RLS subjects. Effect sizes (ES) indicated 
that these differences ranged from medium (around 0.5, d2-cancellation, verbal and category 
fluency) to large (0.8, Stroop task, Table 4). Because RLS subjects differed from controls in 
depression scores, we repeated the analysis for the d2-cancellation task, the Stroop task and 
verbal fluency in a restricted sample of 15 RLS subjects with BDI scores within the normal 
range (0-9). A difference between patients and controls was no longer apparent for the d2-
cancellation task (ES: 0.39) and category fluency (ES: 0.36) while deficits in the Stroop task 
(ES: 1.01; F1,14=8.076, p = 0.013) and letter fluency (ES: 0.72, F1,14=9.467, p = 0.008) 
became even more pronounced. 
To explore potential determinants of these reduced task performances we correlated RLS 
subjects' z-scores in the four tasks with age, RLS severity, sleep quality, subjective sleep 
duration, daytime sleepiness, depression, and psychopathology scores. We also investigated 
whether task performance differed between patients with impaired sleep quality (PSQI > 10), 
increased daytime sleepiness (ESS > 11) or low ferritin levels (< 50 ng/ml) versus patients 
with normal values in the respective measurements. Task performance did not correlate with 
age, sleep quality, sleep duration, daytime sleepiness, or psychopathology scores (rho < 
0.360, p > 0.09). IRLS scores were significantly associated with performance in the d2-
cancellation task (rho = -0.440, p = 0.036). Furthermore, both depression scores (rho = -
0.531, p = 0.011) and IRLS scores correlated with category fluency (rho = -0.612, p = 0.002). 
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There was, however, a strong association between depression scores and RLS severity (rho 
= 0.669, p < 0.001). Partial correlations revealed that the association between IRLS scores 
and category fluency was distinctly attenuated when controlling for depression scores (r = -
0.350, p = 0.110) and vice versa (correlation of depression scores with category fluency 
controlling for IRLS scores: r = -0.295, p = 0.183).  
 
 
Table 4. Cognitive functions in RLS subjects and matched controls (z-scores).  
 RLS Control   
 Mean ± SD Mean ± SD Test statistics, p Effect  
 n = 23 n = 23  size 
Attention   F(5,18) = 3.22 p = 0.030  
D2 Cancellation Test -0.37 ± 1.05 0.09 ± 0.85 F(1,22) = 5.83  p= 0.025 0.49 
Trail-Making Test (ZVT) 0.02 ± 1.28 0.01 ± 0.77 F(1,22) = 0.01  p= 0.963 -0.01 
Digit span forward -0.05 ± 0.75 0.26 ± 1.10 F(1,22) = 1.67  p= 0.209 0.34 
Block span forward 0.63 ± 0.84 0.69 ± 0.98 F(1,22) = 0.43  p= 0.837 0.07 
Stroop task -0.27 ± 1.03 0.41 ± 0.71 F(1,22) = 8.14  p= 0.009 0.78 
Working memory   F(2,21) = 0.35  p = 0.710  
Digit span backward 0.24 ± 0.97 0.19 ± 0.95  -0,05 
Block span backward 0.52 ± 0.97 0.73 ± 0.91  0.23 
Memory (MVG)   F(4,19) = 0.33  p = 0.854  
Immediate recall -0.11 ± 1.32 -0.02 ± 0.90  0.08 
Learning 0.66 ± 0.87 0.69 ± 0.82  0.03 
Delayed recall (short) 0.58 ± 0.93 0.49 ± 0.98  -0.10 
Delayed recall (long) 0.69 ± 0.81 0.49 ± 0.98  -0.23 
Verbal fluency (RWT)   F(2,21) = 3.88  p = 0.037  
Letter fluency -0.20 ± 0.99 0.29 ± 0.86 F(1,22) = 4.77  p = 0.040 0.54 
Category fluency 0.12 ± 1.02 0.56 ± 0.86 F(1,22) = 4.55  p = 0.047 0.48 
Cognitive flexibility (RWT)   F(2,21) = 2.25  p = 0.130  
Alternating letters fluency -0.16 ± 1.04 0.14 ± 1.04  0.29 
Alternating categories fluency 0.11 ± 0.74 0.50 ± 0.82  0.51 
Abstract reasoning     
Raven matrices (n = 22) 1.27 ± 0.62 1.29 ± 0.55 F(1,21) = 0.03  p = 0.869 0.09 
MVG = Münchner Verbaler Gedächtnistest; RWT = Regensburger Wortflüssigkeitstest; ZVT = Zahlenverbindungstest 
 
Cognitive functioning in RLS 
 
 19  19 
 
 
 
Patients with more severely impaired sleep quality (PSQI > 10, n = 15) showed a significantly 
lower performance in the category fluency task than patients with better sleep quality (-
0.21±0.89 vs. 0.74±1.01, t(df=21) = 2.335, p = 0.030, Figure 2). Finally, for 17 of the RLS 
subjects ferritin levels were available, and within this group those with low ferritin (< 50 ng/ml, 
n = 7) showed a worse performance in the letter fluency task (-0.90±0.87 vs. 0.35±0.71, 
t(df=15) = 3.260, p = 0.005, Figure 2).  
 
Discussion 
We compared cognitive functioning of RLS patients to that of individually matched controls 
and found a decreased verbal fluency and selective attention and increased vulnerability to 
So far, there have been only four previous studies exploring cognitive functioning in subjects 
with RLS. Saletu and co-workers10 found that in 12 unmedicated patients with idiopathic RLS 
and matched controls fine motor activity of the left hand was decreased, reaction time was 
slower, and reaction time variability and errors of omission were increased in patients. The 
study of the group of Drs. Allen and Early11 assessed attention, verbal fluency, and executive 
functioning in 16 unmedicated patients with idiopathic RLS and healthy controls. Patients 
performed worse on the Trail-Making Test B and the category verbal fluency task compared  
Fig. 1. Left panel: Significant differences in semantic verbal fluency (measured in z-scores) between 
RLS subjects with more impaired sleep quality (PSQI score > 10) and RLS subjects with less impaired
sleep quality (PSQI score < 10). Right panel: Significant differences in phonemic verbal fluency
(measured in z-scores) between RLS subjects with low ferritin levels (< 50 ng/ml) and those with 
normal ferritin levels. The z-scores represent in standard deviation units the extent to which a raw
performance score deviates relative to German age- and/or gender-specific normative data and show 
a mean of 0 and standard deviation of 1.  
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to controls. In the largest study to date, Celle and co-workers13 reported cognitive functioning 
in RLS subjects in an elderly French population (all 68±1 years). There was no difference 
between 77 subjects with RLS and 241 subjects without RLS in episodic memory, visual 
memory, digit span, trail making tests, and a test of reasoning. However, RLS subjects 
performed worse than controls in verbal fluency and the Stroop task. Recently, a 
retrospective study12 found no differences in a wide range of cognitive performance 
measures between 26 elderly subjects with RLS and 208 control subjects (average age: 77 
years). However, in this group RLS severity was very mild (average IRLS score: 11), RLS 
medications were not withdrawn for testing, concurrent depression was not excluded and 
antidepressant and benzodiazepine use was permitted, which limits the comparability with 
previous studies and impedes the interpretation of negative findings.  
The overlap with the study of Saletu and co-workers10 is small but nevertheless the numerical 
memory tasks of this study are similar to the digit span employed in the present study, and in 
both studies no difference between RLS subjects and controls was found. Our finding of 
reduced verbal fluency matches those reported by Pearson et al.11 and Celle et al.13. In the 
present study and the study of Celle et al. both letter and category fluency were affected 
while in the study of Pearson et al. a significant difference was reported only for category 
fluency. Since in the latter work there was a trend (p = 0.09) also towards reduced letter 
fluency, the smaller sample size and reduced statistical power could explain this difference. 
Both studies11,13 also employed a version of the Trail-Making task A, a measure of attention, 
and like the present study found no difference. Likewise, performance in Raven's 
Progressive Matrices, a measure of reasoning, did not differ between RLS subjects and 
controls in Pearson's and the present study. All three studies, however, also employed the 
Stroop task. Pearson et al. reported no differences in performance, Celle et al. found that 
RLS subjects were slower in word and color naming but not the color word naming, and we 
found a strong effect for this task. Potential explanations for these varying findings are 
differences in the samples employed or the specific scoring of the Stroop task. We have 
analyzed z-scores of performance, while the other two studies computed the raw difference 
between color naming and color word naming. However, in our sample also the raw 
performance scores for the Stroop task differed significantly between RLS subjects and 
controls (39.83±18.59 vs. 28.26±11.10; tdf=22 =3.22, p = 0.004; effect size d = 0.77). On 
average RLS subjects were 10 years older in Pearson's study and 14 years older in the 
French study. The difference in the average age of subjects could suggest that the Stroop 
task is more sensitive in a middle-aged as opposed to an elderly population, perhaps 
because the strong age-related decrease in performance obscures group differences41.  
In post-hoc analyzes we found that RLS severity was associated with selective attention and 
ferritin status with letter fluency which had not been documented before. Iron deficiency can 
affect cognitive performance also in adults42-44, and the potential influence of iron status on 
cognitive performance in RLS subjects warrants further systematic investigation. For 
category fluency we observed a strong association with both RLS severity and depression 
scores, and RLS subjects with more severely impaired sleep quality showed decreased 
category fluency. All three factors, however, were not independent from each other 
suggesting that the influence of RLS severity on cognitive functioning was mediated by mood 
and sleep quality and vice versa. To disentangle the separate contribution of these factors a 
larger group with a broader range of symptoms would be needed. Our subgroup analysis in 
patients without elevated depression scores showed, however, that cognitive deficits in RLS 
patients are still evident in this group.  
Potential limitations of the present study are sample selection and study design. We included 
consecutive RLS outpatients and thus the sample was representative of RLS sufferers, i.e. 
patients with severe and frequent RLS symptoms, at least severe enough to seek 
Cognitive functioning in RLS 
 
 21  21 
professional help. However, RLS subjects had to be medication-free for at least 2 weeks, 
and this might have introduced a bias towards less severely affected patients. By including 
consecutive patients we also increased heterogeneity of the sample with regard to age, RLS 
severity, treatment history, and other factors that thereby might have obscured patient-
control differences. We did not record objective data documenting sleep disturbances and 
periodic limb movements or the absence of sleep disorders in the control group. While both 
patients and controls were interviewed by a sleep specialist, sleep disorders cannot be ruled 
out with complete certainty without polysomnography. It also precluded us from associating 
objective indices of sleep disturbances with cognitive functioning in RLS, a topic that merits 
further investigation. 
In summary, subjects with RLS showed specific and significant impairments in selective 
attention, vulnerability to interference, and verbal fluency, which are partly influenced by RLS 
severity, sleep disturbances, and iron status. Further research is needed to replicate these 
determining factors, which could then be used to identify RLS patients at risk for cognitive 
dysfunctions.  
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III. Where dopamine meets opioids: a meta-analysis of the 
placebo effect in restless legs syndrome treatment 
studies* 
This is a pre-copy-editing, author-produced PDF of an article accepted for publication in 
BRAIN following peer review. The definitive publisher-authenticated version [Where 
dopamine meets opioids: a meta-analysis of the placebo effect in RLS treatment studies. 
Stephany Fulda, Thomas C. Wetter. Brain 2007; DOI 10.1093/brain/awm244] is available 
online at: 
 http://brain.oxfordjournals.org/cgi/reprint/awm244?ijkey=HHziocBtzVBsqWZ&keytype=ref  
Abstract 
The restless legs syndrome (RLS) is a common sensory-motor disorder of sleep/wake motor 
regulation with prevalence rates between 3% and 10%. In its more severe forms, RLS is a 
burdening disorder with disturbed sleep and significantly impaired quality of life. Restless 
legs symptoms are dramatically relieved with levodopa and dopamine agonists, which are 
first-line treatment for this disorder. In addition, opioids have been shown to provide a 
marked symptomatic relief. This unique responsiveness of RLS to both dopaminergic agents 
and opioids places it at the crossroad of the two systems implicated in the placebo response. 
Indeed, in recent large-scale studies a substantial placebo response was observed. We 
performed a meta-analysis to provide an evidence-based estimate of the magnitude of the 
placebo response in RLS.  
Search strategies included the electronic databases PubMed and the Cochrane Clinical 
Trials Registry (from1966 to March 2007), the reference lists of retrieved articles, hand-
searching abstract books of sleep, neurology and movement disorder congresses and 
visiting clinical trial register web sites. All randomized, double-blind, placebo-controlled 
studies exploring a pharmacological treatment in subjects with RLS were considered. 
Outcome measures from five domains were extracted: RLS severity, subjective sleep 
parameters, sleep parameters derived from nocturnal polysomnography, periodic leg 
movements during sleep (PLMS) and daytime functioning.  
We identified 60 clinical trials and 36 of them were eligible for the meta-analysis. In 24 trials, 
the pooled placebo response rate was 40.09% (95% CI: 31.99 - 48.19). The placebo effect 
was large for the primary outcome measure in most studies, which is the International 
Restless Legs Severity Scale (21.48, CI: 21.81 to 21.14), notably smaller for other RLS 
severity scales, moderate for daytime functioning, small to moderate for subjective and 
objective sleep parameters, very small for PLMS and absent for sleep efficiency.  
This meta-analysis yields several implications for the planning of both clinical RLS treatment 
studies and basic research programs.  
Keywords: restless legs syndrome; placebo effect; meta-analysis  
Abbreviations: CGI=Clinical Global Impression; CI=confidence interval; CO=cross-over trial; 
ES=effect size; IRLS=International Restless Legs Severity Scale; PD=Parkinson’s disease; 
PG=parallel-group trial; PLMS=periodic leg movements during sleep; RLS=restless legs 
syndrome 
 
                                                 
* Fulda S, Wetter TC. Where dopamine meets opioids: a meta-analysis of the placebo effect in restless 
legs syndrome treatment studies. Brain 2008; 131: 902-917. 
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Introduction  
The placebo response is an improvement of subjective and objective outcomes while taking 
an inert substance or undergoing a sham procedure. The precise mechanisms of the placebo 
response are not well understood (Hróbjartsson and Gøtzsche, 2001) and potential factors 
include regression to the mean, expectancies, non-specific effects of participating in research 
and physiological changes produced by placebos. The dopamine and opioid systems are 
thought to play a crucial role in the physiological response to a placebo (Colloca and 
Benedetti, 2005). The placebo effect in pain is powerful and has been known for long (Levine 
et al., 1978; Turner et al., 1994; Colloca and Benedetti, 2005); placebo analgesia can be 
blocked by naloxone, suggesting that placebos can induce the release of endogenous 
opioids (Levine et al., 1978; Amanzio and Benedetti, 1999; Benedetti et al., 1999). In a 
positron emission tomography (PET) study, analgesia induced by both a placebo and the 
opioid agonist remifentanil was associated with an increased activity in several pain-
modulating brain regions including the rostral anterior cingulate cortex, the orbitotofrontal 
cortex and the anterior insula (Petrovic et al., 2002). Functional magnetic resonance imaging 
(fMRI) showed an increased activation in the same regions and in the dorsolateral prefrontal 
cortex during the anticipation phase of the placebo analgesic response, whereas placebo 
treatment was characterized by a decreased activation in the thalamus, anterior insula and 
the caudal rostral anterior cingulate cortex (Wager et al., 2004). A substantial placebo effect 
is also apparent in neurological disorders not directly involving pain such as Parkinson’s 
disease (PD) (Shetty et al., 1999; Goetz et al., 2002). The dopaminergic system, particularly 
affected in PD, is involved in the regulation of several cognitive, behavioural and sensory-
motor functions (Nieoullon, 2002), and notably in reward mechanisms (Ikemoto and 
Panksepp, 1999; Martin- Soelch et al., 2001). PET studies using the dopamine D2 receptor 
antagonist [11C]raclopride found that the placebo effect in PD is related to the release of 
dopamine in both the dorsal (de la Fuente-Fernández et al., 2001) and ventral striatum (de la 
Fuente-Fernández et al., 2002). In addition, the perception of the clinical placebo effect was 
related to the amount released in the dorsal striatum (de la Fuente- Fernández et al., 2001). 
 A disorder that is unique in the sense that it responds to both dopaminergic and opioidergic 
agents is the restless legs syndrome (RLS). RLS is a common sensory-motor disorder of 
sleep/wake motor regulation with prevalence rates estimated from population surveys 
between 3% and 10% (Phillips et al., 2000; Masood and Phillips, 2003). RLS is characterized 
by an imperative desire to move the extremities associated with paraesthesias, motor 
restlessness, worsening of symptoms at rest and in the evening or at night and, as a 
consequence, sleep disturbances (Allen et al., 2003). Additionally, most patients with RLS 
have periodic limb movements during sleep (PLMS) and relaxed wakefulness. In its more 
severe forms, RLS is a burdening disorder with significantly impaired quality of life (Hening et 
al., 2004). Restless legs symptoms are dramatically relieved with levodopa and dopamine 
agonists, which present first-line treatment (Fulda and Wetter, 2005), and this 
responsiveness is a supportive criterion for the diagnosis of RLS (Allen et al., 2003). In 
contrast to PD, RLS is not a degenerative disorder, and a dopaminergic deficit has not been 
proven (Paulus and Trenkwalder, 2006). So far, PET and single photon emission 
tomography (SPECT) studies are at best compatible with a subtle dysfunction of the 
dopaminergic system (Wetter et al., 2004). The sensory symptoms of RLS may be 
experienced as painful by a substantial number of patients (Winkelmann et al., 2000) and 
opioids have been shown to provide a marked symptomatic relief (Kaplan et al., 1993; 
Walters et al., 1993). Again, imaging results did not reveal major changes in opioid receptor 
binding. However, in a recent PET study using the non-selective opioid receptor ligand 
[11C]diprenorphine, RLS severity correlated negatively with ligand binding in the medial pain 
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system including the thalamus, the amygdala and the anterior cingulate gyrus (von Spiczak 
et al., 2005).  
The unique responsiveness of RLS to both dopaminergic agents and opioids places it at the 
crossroad of the two systems implicated in the placebo response. In addition, substantial 
placebo effects have also been reported in a broad spectrum of disorders of the central 
nervous system such as insomnia (Perlis et al., 2005) and depression (Walsh et al., 2002; 
McCall et al., 2003), both conditions that are also associated with RLS (Picchietti and 
Winkelman, 2005). And indeed, in recent treatment trials, a large placebo effect has been 
observed (Allen et al., 2004; Trenkwalder et al., 2004; Walters et al., 2004). The aim of the 
present meta-analysis was to quantify the magnitude of the placebo effect in RLS treatment 
studies by combining results from studies conducted during the past 25 years. We also 
explored whether the placebo effect differed between the various outcome modalities 
assessed in RLS treatment trials such as RLS severity, periodic leg movements, subjective 
and objective assessment of sleep and daytime functioning.  
 
Methods 
Location and selection of studies 
We searched the electronic databases PubMed and the Cochrane Clinical Trials Registry 
(from 1966 to March 2007) using the following key words: ‘restless legs syndrome’ and 
‘placebo’. In addition, reference lists of the retrieved articles were checked and we made an 
extensive effort to include unpublished material and trial information published only as 
abstracts by hand-searching abstract books of sleep, neurology and movement disorder 
congresses held in the last 4 years and visiting trial register web sites of companies known or 
suspected to conduct trials (Supplement 1 lists all resources used for the search). All 
randomized, double-blind, placebo-controlled studies exploring a pharmacological treatment 
in subjects with RLS were considered. Exclusion criteria were the use of concomitant 
pharmacological treatment for RLS during the trial and a withdrawal study design. We also 
considered non-English publications. A detailed list of the excluded studies with the reason 
for exclusion is available from the authors on request.  
 
Outcome measures  
For this meta-analysis, in addition to analysing response rates, we focused on five general 
domains that have been addressed in RLS treatment trials: RLS severity, subjective sleep 
parameters, sleep parameters derived from nocturnal polysomnography, PLMS and daytime 
functioning. Within each domain we selected those outcomes for which at least five effect 
sizes could be extracted. These were available for the International Restless Legs Severity 
Scale (IRLS) (Walters et al. 2003) and other RLS severity scores, subjective sleep duration 
and sleep quality, total sleep time and sleep efficiency derived from polysomnography, the 
PLMS index (number of periodic leg movements per hour of sleep), daytime sleepiness and 
quality of life.  
 
Data extraction and computation of effect sizes  
One reviewer extracted data and another reviewer verified the data extracted. Calculation of 
effect sizes and variances followed the general outline given by Morris and DeShon (2002) 
(for computational details see Appendix I). Effect sizes were computed for all outcome 
measures where means and standard deviations (SD, or standard errors) were given for 
baseline and endpoint of the placebo trial or for the differences between baseline and 
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endpoint. The effect size employed in this meta-analysis expressed the differences between 
baseline and endpoint in units of the standard deviation at baseline:  
mean at baseline – mean at endpoint  
ES =  
SD at baseline  
All effect sizes were corrected for small sample bias following Hedges (1982). The sampling 
variance for the individual effect size was computed taking into account the correlation 
between baseline and endpoint (Morris and DeShon 2002) (see Appendix I). These 
correlations are rarely reported but can be computed by combining variances from baseline, 
endpoint and difference scores. The estimated correlations between baseline and placebo 
endpoint were 0.39 for the IRLS and other scales (n = 665, eight studies), 0.78 for subjective 
sleep parameters (n = 305, three studies), 0.91 for polysomnographic sleep parameters (n = 
17, two studies), 0.71 for the PLMS index (n = 126, three studies) and 0.92 for daytime 
functioning (n = 195, two studies) (see Appendix II for specific references).  
A random effects meta-analysis was conducted to yield a pooled estimate of the placebo 
effect and between-study heterogeneity assessed with the homogeneity index I2. In case of 
significant between-study heterogeneity (I2 > 25%), an attempt was made to find a 
homogeneous set of effect sizes by excluding studies based on study characteristics. A priori 
defined variables for the subgroup analysis were study design (parallel-group versus cross-
over design), study duration (84 versus <84 days; 430 versus 535 days), number of 
treatment arms (one versus more than one), study population (idiopathic versus secondary 
RLS), study drug (dopaminergic versus non-dopaminergic drug) and outcome measures 
where applicable (e.g. periodic leg movements assessed with actigraphy versus 
polysomnography).  
For descriptive purposes only, we also computed the corresponding effect sizes in the 
treatment groups for each outcome and explored whether treatment and placebo effect sizes 
were associated (Spearman correlation ρ). In trials employing multiple groups, treatment 
effects were taken from the group with the largest effect. Results are displayed as forest 
plots with the familiar diamond shape of the effect sizes replaced by circles to indicate that 
these are repeated-measures effect sizes instead of the standard independent group effect 
sizes. Analysis of response rates followed the general outline of Einarson (1997) but with 
confidence intervals of the point estimates computed according to Wilson (Agresti and Coull 
1998). All analyses were performed with R (R Development Core Team, 2005) and the meta 
and nlme library (Pinheiro and Bates, 2000) in R.  
 
Meta-regression  
Meta-regression employing linear mixed models with known level-1 variance (Raudenbush 
and Bryk, 2002) and effect sizes nested within studies was employed to explore two basic 
questions. First, for response rates, the role of those study characteristics used for subgroup 
analysis (see above) was assessed. Initially, several other trial characteristics such as 
percentage of drug-naïve patients, mean age, gender composition, or severity of RLS were 
considered, but too little information was available in the first case and not enough variation 
was found in the latter variables (Table 1). Second, for the RLS severity measures, we 
explored whether differences between the IRLS and other scores persisted after controlling 
for differences in study characteristics. We chose not to perform meta-regression for the 
other outcome measures or for all available effect sizes due to several reasons: study design 
and study duration were not independent and both were associated with the year of 
publication and sample size, thus there was considerable confounding of the potential 
moderator variables. This was mostly due to the fact that all newer studies (after 2002) were 
long-term (12 weeks), parallel-group trials with large sample sizes. In addition, the use of 
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specific outcome measures was also associated with these trial characteristics. In particular, 
effect sizes for quality of life were only available for long-term, parallel-group studies and the 
IRLS and subjective sleep duration were mostly available from parallel-group trials. 
 
 
Placebo group   
Drug 
 
Study 
design 
 
 
P:D 
 
P:D 
n 
 
Study 
duration 
(days)a 
Age 
(mean) 
Female 
(%) 
Drug 
naïve 
(%) 
Id:Sec 
nb 
Dopaminergic drugs         
Levodopa         
 Montplaisir et al., 1996  SC CO 1:1 6 14:7 51 50 100 6:0 
 Beneš et al., 1999 MC CO 1:1 32 28:0 56 59 50 28:4c 
Levodopa + entacapone         
 Polo et al., 2005 CO 1:4 28 1:6 51 64   
Sr-levodopa / sr-valproic acid         
 Eisensehr et al., 2004 CO 1:2 20 21:0 59 60  20:0 
Bromocriptine         
 Walters et al., 1988 SC CO 1:1 6 30:14 61 33  6:0 
Pergolide         
 Wetter et al., 1999 MC CO 1:1 28 28:7 57 57 36 28:0 
Ropinirole         
 GlaxoSmithKline, 2005b; 
Trenkwalder et al., 2004 MC PG 1:1 
138:14
6 
84 56 66  284:0 
 GlaxoSmithKline, 2005c; 
Walters et al., 2004 MC PG 1:1 
135:13
1 
84 56 62 57 266:0 
 Allen et al., 2004; 
GlaxoSmithKline, 2005d MC PG 1:1 30:29 84 53 57 50 
59:0 
 
 Kelly and Mistry, 2005 MC PG 1:2 17:37 42 56 76  54:0 
 Bogan et al., 2006; 
GlaxoSmithKline, 2005a MC PG 1:1 
193:18
7 
84 52 64  380:0 
 GlaxoSmithKline, 2006b; 
Kushida and Tolson, 2006 MC PG 1:1 
184:17
5 
84 51 62  
359:0 
 
 GlaxoSmithKline, 2006a 
MC PG 1:1 
149:15
4 
84 57 75  303:0 
 Adler et al., 2004 CO 1:1 22 28:7 60 73 59 22:0 
Pramipexole         
 Montplaisir et al., 1999 SC CO 1:1 10 28:14 49 50 60 10:0 
 Oertel et al., 2006b 
MC PG 1:1 
114:22
4 
42 56 68 68 338:0 
 Partinen et al., 2006 PG 1:4 22:86 21 53 81 67 107:0 
 Winkelman et al., 2006 MC PG 1:3 85:254 84 52 64 81 339:0 
 Inoue et al., 2006 PG 1:1 19:19d 42     
Cabergoline         
 Kohnen et al., 2004; 
Stiasny-Kolster et al., 2004a MC PG 1:3 22:63 35 56 82 36 85:0 
 Oertel et al., 2006a MC PG 1:1 20:20 35 56 75 20 40:0 
      continued on next page 
Table 1 Study description including study design, placebo-drug allocation, study duration, age, gender, 
percentage of drug-naïve patients and number of idiopathic and secondary RLS patients 
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Table 1 continued 
Lisuride patch         
 Beneš et al., 2005 MC PG 1:3 52:156d 84 60b 70b  206:4c 
Rotigotine patch         
 Stiasny-Kolster et al., 2004b MC PG 1:3 14:49 7 60 50 14 63:0 
 Oertel et al., 2005 MC PG 1:5 55:285 49 58b 70b  340:0 
Sumanirole         
 Garcia-Borreguero et al., 2007 MC PG 1:4 52:218 56 53 58  270:0 
Anticonvulsant drugs         
Carbamazepine         
 Lundvall et al., 1983 CO 1:1 6 28:0 53 33   
 Telstad et al., 1984 MC PG 1:1 90:84 35 52 72   
Gabapentin         
 Garcia-Borreguero et al., 2002 SC CO 1:1 22 42:7 55 73  22:2e 
 Thorp et al., 2001 SC CO 1:1 16 42:7 64 6  0:16c 
XP13512         
 Kushida et al., 2006 MC PG 1:2 33:62 14 50b 62b   
 XenoPort 2006 MC CO 1:1 36 14:7 50 58   
Opioids         
Oxycodone         
 Walters et al., 1993 MC CO 1:1 11 14:0 55 45  11:0 
Other drugs         
Clonazepam         
 Boghen et al., 1986 SC CO 1:1 6 28:0 46 50   
 Montagna et al., 1984 SC CO 1:2 6 7:3 54 50   
Clonidine         
 Wagner et al., 1996 MC CO 1:1 10 14:0 44 20  10:0 
Hydroquinine         
 van Dijk et al., 1991 SC CO 1:1 59 14:14 55 47   
P : D: placebo : drug allocation, Id : Sec: idiopathic : secondary RLS, SC: single-centre, MC: multi-centre, CO: cross-over, PG: 
parallel-group, 
a study duration : duration of wash-out phase 
b complete group 
c uremic RLS 
d The exact number of participants in each group was not reported but estimated as being the appropriate fraction of the total 
numbers. 
e iron deficiency 
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Fig. 1. Process of study selection of randomized controlled trials. (RLS: restless legs syndrome, IRLS:
International Restless Legs Severity Scale). 
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Results  
We identified 60 double-blind, randomized, placebo-controlled studies. Twenty-four studies 
were excluded for various reasons detailed in Fig. 1 and we included 36 studies published 
between 1983 and 2007. A detailed description of the included studies is given in Table 1. 
There were 17 crossover trials and 19 parallel-group trials with study durations between 1 
day and 12 weeks (Table 1). The vast majority of trials included patients with idiopathic RLS, 
with three trials including also a low number of subjects with secondary RLS and one trial 
including only subjects with uraemic RLS. Summing over all trials, there were 1748 subjects 
in the placebo groups. The average age was 54 years (range: 44–64 years) and around 64% 
of the participants were female with the proportion ranging from 6% to 82%.  
 
Response rates  
Twenty-four studies reported response rates during placebo treatment (see Appendix 2.2 for 
specific references). In 17 studies, response rates were given as percentage of patients 
rated as ‘much improved’ or ‘very much improved’ on the clinical global impression (CGI) 
change of condition scale by the physician. One study defined response rates as an IRLS 
score indicative of none or mild symptoms; two studies relied on physician-rated 
improvement and in a single study each response was defined on a self-made RLS symptom 
scale, as no RLS ‘attacks’ during 1 week, or the wish to continue on placebo medication. 
Finally, for one study response rates pertaining to different scales were reported and 
averaged within study to yield a single estimate. The 24 studies included a total of 1527 
patients in the placebo condition and 1665 patients in the treatment condition. Placebo 
response rates varied from 0% to 60% with substantial heterogeneity (I2 = 91.6%, Fig. 2). We 
considered several subgroups of studies based on study characteristics (see Methods 
section and Supplement 2) but were not able to find a homogeneous set of effect sizes so 
that a random effects model was applied. The pooled weighted response rate during placebo 
treatment was 40.09% [95% confidence interval (CI): 31.99–48.19]. The corresponding mean 
weighted response rate in the treatment groups was 68.32% (CI: 63.36–73.29), again with 
significant between-study heterogeneity (I2 = 77.3%). Placebo and treatment response rates 
did not correlate across studies (ρ 0.22, P = 0.30). We conducted a linear mixed model meta-
regression with fixed level-1 variances of 41 available response rates from 24 studies 
including 17 additional effect sizes from eight studies that reported response rates for more 
than one time point during the trial and with the study characteristics as covariates. Of all the 
study characteristics only study duration was related to the placebo response which 
increased with study duration both within and across studies (Supplementary Fig. 1). Given 
an estimated placebo rate of 22.26% (±3.02, t = 7.36, P < 0.0001) at the end of the first week, 
the response rate during placebo treatment is expected to increase by almost 3% per week 
(2.75±0.19, t = 14.47, P < 0.0001). 
 
IRLS and other RLS scores 
A total of 22 studies reported placebo data regarding RLS symptom scales. The IRLS was 
the primary or secondary endpoint in 14 studies (see Appendix II for specific references); in 
four of these studies additional scales for rating restless legs symptoms have been employed 
as well. A further eight studies used other scores such as the RLS-6 scales, visual analogue 
scales of RLS severity, the CGI severity of RLS item, the number of RLS ‘attacks’ per week 
or various self-made RLS scores, with three studies reporting aggregated data for a 1-week 
diary of symptoms. Most studies that did not use the IRLS employed several different scores 
to assess RLS severity; these were averaged within study to yield a single effect size
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estimate. Standardized repeated-measures effect sizes for the IRLS ranged from -0.04 
to -2.67 with significant between-study heterogeneity (I2 = 89.0%, Fig. 3). Excluding the only 
crossover trial did not yield a homogeneous data set (I2 = 87.5%) nor did restricting the 
analysis to trials with the longest study duration (I2 = 90.5%, Supplement 2). The pooled 
random-effects estimator was -1.48 (CI: -1.81 to -1.14), which indicates a substantial 
decrease of RLS severity during placebo treatment. The corresponding pooled random-effect 
size for the treatment condition was -2.62 (CI: -2.97 to -2.27), again exhibiting significant 
between-study heterogeneity (I2 = 84.2%). There was a positive correlation between the 
treatment and placebo effect sizes for the IRLS (ρ = 0.53, P = 0.05).  
The standardized repeated-measures effect sizes for other RLS severity scores ranged from 
0.04 to -1.21 with significant between-study heterogeneity (I2 = 75.3%, Fig. 3). Between-
study heterogeneity was no longer apparent when considering only the seven cross-over 
trials (I2 = 0%), while it was still substantial for the parallel-group trials (I2 = 87.0%). The 
pooled placebo effect sizes were -0.25 (CI: -0.49 to -0.01) for the cross-over trials and -0.78 
(CI: -1.26 to -0.30) for the parallel-group trials. The corresponding pooled treatment effect 
Fig. 2. Meta-analysis of response rates during placebo treatment in RLS therapy studies (CO: cross-
over trial, PG: parallel-group trial, CI: confidence interval). 
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sizes were -1.57 (CI: -2.21 to -0.94; I2 = 58.8%) for the cross-over trials and -1.48 (CI: -1.99 
to -0.98; I2 = 86.0%) for the parallel-group trials. There was no correlation between placebo 
and treatment effect sizes for the cross-over trials (ρ -0.04, P = 0.96), but a positive 
correlation for the parallel-group trials (ρ 0.70, P = 0.23). 
We conducted a linear mixed model meta-regression with fixed level-1 variances of 31 
available effect sizes from 22 studies including five additional effect sizes from four studies 
that reported RLS severity for more than one time point during the trial and with the type of 
scales (IRLS versus all other scores) and study characteristics as covariates. The pooled 
placebo effect was of greater magnitude for the IRLS than for other scales (-0.79±0.29, t = -
2.72, P = 0.03) when considering only marginal effects. When controlling for study duration 
and type of trial, the differences in effect sizes between the different scales were still evident 
(-0.52±0.17, t =-3.01, P = 0.02) while there was only a trend for a larger placebo effects in 
Fig. 3. Meta-analysis of standardized repeated-measures effect sizes for the placebo effect in the 
IRLS scale and other RLS severity scores (IRLS: International Restless Legs Severity Scale, RLS:
restless legs syndrome, CO: cross-over trial, PG: parallel-group trial, CI: confidence interval). 
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parallel-group trials versus crossover trials (-0.55±0.27, t =-2.01, P = 0.06). The placebo 
effect increased with study duration and each additional week was estimated to further 
reduce RLS severity by the standardized effect size of 0.09 (±0.01, t =9.62, P < 0.0001).  
 
Subjective sleep parameters: sleep quality and sleep duration  
Twelve studies reported data on sleep quality during placebo treatment (see Appendix II for 
specific references). Outcomes included the Medical Outcome Study Sleep Scale item ‘sleep 
adequacy’ in six studies, the Schlaffragebogen A item ‘sleep quality’, the RLS-6 item ‘sleep 
satisfaction’, a visual analogue scale item ‘satisfaction with sleep’ and diary-derived sleep 
quality. Repeated-measures effect sizes ranged from 0.00 to 0.46 with significant between-
study heterogeneity (I2 = 70.7%) that remained after the exclusion of the three crossover 
trials (I2 = 73.4%). The pooled placebo effect size estimate was 0.27 (CI: 0.18–0.36), 
indicative of a small increase in sleep quality during placebo treatment (Figure 4, upper 
panel). The corresponding pooled treatment effect size was 0.84 (CI: 0.63–1.04; I2 = 92.3%). 
The correlation between placebo and treatment effect sizes was negative but statistically 
insignificant (ρ -0.22, P = 0.50).  
Subjective sleep duration was reported in seven trials (see Appendix II for specific 
references); six of them employed the Medical Outcome Study Sleep Scale item ‘sleep 
quantity’ and one study reported a diary-based estimate. Repeated-measures effect sizes 
ranged from -0.15 to 0.32 with significant between-study heterogeneity (I2 = 78.2%) that 
remained after the exclusion of the only crossover study that was also the only study with a 
study duration less than 12 weeks (I2 = 81.4%). The pooled random-effects estimate was 
0.13 (CI: 0.03–0.24) pointing to a very small, albeit statistically significant increase in 
subjective sleep duration during placebo treatment (Fig. 4, upper middle panel). The 
corresponding pooled treatment effect size was 0.35 (CI: 0.23–0.47; I2 = 76.6%) and there 
was a positive correlation between placebo and treatment effect sizes (ρ 0.54, P = 0.236).  
 
Polysomnographic sleep parameters: sleep efficiency and total sleep time  
Five studies reported data regarding the placebo effect on total sleep time with repeated-
measures effect sizes ranging from 0.05 to 0.59 with moderate to substantial heterogeneity 
(I2 = 68.2%) (see Appendix II for specific references). The pooled effect size of 0.24 (CI: 
0.04–0.44) was indicative of a small increase in total sleep time during placebo treatment 
(Fig. 4, lower middle panel). The corresponding pooled treatment effect size was 0.37 (CI: 
0.25–0.49; I2 = 0%) and there was a positive but statistically insignificant correlation between 
placebo and treatment effect sizes (ρ 0.60, P = 0.35). Seven studies reported data regarding 
sleep efficiency with effect sizes ranging homogeneously (I2 = 37.2%) from -0.21 to 0.25 
around the pooled effects estimate of 0.07 (CI: -0.06–0.19) which did not significantly differ 
from zero (Fig. 4, lower panel) (see Appendix II for specific references). The corresponding 
pooled treatment effect size was 0.37 (CI: 0.26–0.49; I2 = 0%) and there was a negative 
association between placebo and treatment effect sizes (ρ -0.60, P = 0.24).  
 
PLMS  
Fourteen studies measured the PLMS index during placebo treatment and individual effect 
sizes ranged from 0.44 (increase in PLMS index) to -0.28 (see Appendix II for specific 
references). As shown in Fig. 5, the pooled effect size estimate was -0.11 (CI: -0.20 to -0.03) 
and there was no indication of significant within-study heterogeneity (I2 = 10.5%). The 
corresponding pooled treatment effect size was -0.88 (CI: -1.06 to -0.71; I2 = 52.4%) with no 
apparent correlation between placebo and treatment effect sizes (ρ 0.27, P = 0.34).  
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and there was no indication of significant within-study heterogeneity (I2 = 10.5%). The  
Fig. 4. Meta-analysis of standardized repeated-measures effect sizes for the placebo effect in sleep 
quality (upper panels), subjective sleep duration (upper middle panel), total sleep time derived from
polysomnography (lower middle panel) and sleep efficiency derived from polysomnography (lower
panel) (CO: cross-over trial, PG: parallel-group trial, CI: confidence interval). 
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Daytime functioning: sleepiness and quality of life  
Thirteen studies contributed data concerning daytime sleepiness; six studies employed the 
MOS item daytime sleepiness, three studies used the Epworth Sleepiness Scale, two studies 
reported diary-derived measures of daytime fatigue or drowsiness and one study each used 
the RLS-6 item daytime tiredness or the IRLS item sleepiness (see Appendix II for specific 
references). A decrease in average daytime sleepiness was observed in all studies with 
effect sizes ranging from -0.07 to -0.96 with significant between-study heterogeneity (I2 = 
92.3%). The between-study heterogeneity remained elevated even when considering only 
the parallel-group trials (I2 = 93.7%) or, within that group of studies, only those that used the 
MOS daytime sleepiness item (I2 = 95.4%, Supplement 2). The pooled random effects 
estimate over all studies was -0.36 (CI: -0.48 to -0.25, Supplementary Fig. 2) indicating a 
moderate reduction in daytime sleepiness during placebo treatment. The corresponding 
pooled treatment effect size was -0.63 (CI: -0.80 to -0.46) with significant between-study 
heterogeneity (I2 = 95.4%). Placebo and treatment effect sizes were significantly related 
across studies (ρ 0.87, P < 0.001).  
Seven studies assessed quality of life in RLS subjects (see Appendix II for specific 
references). Six of the seven studies were parallel-group, 12-week studies that employed the 
RLS-Quality of Life Questionnaire (Abetz et al. 2004). One study used a German disease-
specific RLS quality of life questionnaire (Kohnen et al. 2002). Effect sizes ranged from 0.30 
to 1.08 with significant between-study heterogeneity (I2 = 95.1%) that was not reduced after 
the exclusion of the only crossover study (I2 = 94.9%, Supplement 2). The pooled effect size 
was 0.50 (CI: 0.32–0.68, Supplementary Fig. 3) indicating a moderate improvement in quality 
of life during placebo treatment. The corresponding pooled treatment effect size was 0.83 
(CI: 0.58–1.09; I2 = 95.7%). The rank order of treatment and placebo effect sizes across 
studies was in high concordance (ρ 0.96, P = 0.003). 
 
 
Fig. 5. Meta-analysis of standardized repeated-measures effect sizes for the placebo effect in the 
number of periodic leg movements per hour of sleep (PLMS index) (CO: cross-over trial, PG: parallel-
group trial, CI: confidence interval). 
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Discussion 
Our meta-analysis has revealed a substantial placebo response rate in RLS treatment 
studies. On average, more than one-third of RLS subjects experienced a major improvement 
of RLS symptoms while being treated with a placebo. This response rate was matched by a 
large placebo effect in overall RLS severity as measured by the IRLS. Compared to the IRLS, 
other scores of RLS severity had a lower—small to moderate—placebo effect even when 
accounting for differences in study design and study duration. There was a moderate effect 
for quality of life, and a smaller placebo effect was observed for daytime sleepiness, sleep 
quality and total sleep time. Even smaller placebo effects were apparent for subjectively 
estimated sleep duration and the PLMS index. A placebo effect was absent for sleep 
efficiency. Any discussion of differences in the magnitude of the placebo effect must, 
however, take the correlation between the placebo and treatment effect sizes into account. 
Therefore, in Fig. 6, the weighted mean placebo and treatment effect sizes are given for 
each outcome domain and in general the placebo effect size was proportional to the 
corresponding treatment effect size. Although linear mixed model analysis indicated that the 
placebo effect for the IRLS was larger than for other RLS scales even when taking 
differences in study features into account, it is apparent that this large placebo effect was 
also matched by a large treatment effect. Nevertheless, there were some notable exceptions 
to this proportionality of placebo and treatment effect sizes: the placebo effect for RLS scores 
other than the IRLS was considerably smaller in crossover trials than in parallel-group trials, 
while this difference was not observed for the treatment effects. For both sleep quality and in 
particular the PLMS index the treatment effects were disproportionally larger than the 
placebo effects.  
Focusing on PLMS as a primary endpoint in RLS trials could appear promising but neglects 
the fact that only around 80% of subjects with RLS will exhibit PLMS to some degree 
(Montplaisir et al., 1997), thus making generalizations regarding the complete population of 
RLS sufferers questionable. In addition, the true clinical significance of PLMS still remains to 
be determined (Mahowald, 2003). Intriguingly from a theoretical point of view, PLMS are not 
consciously experienced due to their occurrence during sleep and it is tempting to speculate 
that therefore they might not be accessible to placebo-mediated expectations of the subject. 
In addition, apart from the distinction between PLMS and IRLS as subjective versus objective 
outcome measures, the IRLS is a multidimensional assessment instrument, whereas the 
PLMS index is one-dimensional. This multidimensionality of the IRLS may predispose the 
scale to be especially sensitive to placebo but also treatment effects. Future research, 
analysing individual items of the IRLS, should address the question whether this sensitivity 
can be traced back to a specific subset of items. Furthermore, as only a few studies (four) 
have employed another RLS severity score alongside with the IRLS, a direct comparison of 
the IRLS to other measures of severity was not feasible in the present analysis. In addition, 
the majority of response rates included in our analysis were based on the CGI and evaluated 
by an experienced investigator; thus, the placebo effect was not limited to the patients’ self-
report. Interestingly, for PD a recent study (Goetz et al., 2002) found a larger placebo effect 
for the objective part of the Unified Parkinson’s Disease Rating Scale than for the subjective 
part, arguing against a purely subjective phenomenon.  
A placebo effect has been observed in a broad spectrum of disorders of the central nervous 
system such as insomnia or depression and can be attributed to different mechanisms 
including expectation of clinical improvement and conditioning. For both insomnia and 
depression, comparable placebo effects have been reported (Walsh et al., 2002; McCall et 
al., 2003). In both disorders the placebo response increased with study duration (Walach and 
Maidhof, 1999; Perlis et al., 2005; Posternak and Zimmerman, 2005), a phenomenon we 
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observed also for response rates and RLS severity. Indeed, a recent review of the potential 
mechanisms of the placebo response in insomnia highlighted the importance of the episodic 
rather than chronic pattern of insomnia symptoms with regard to the placebo response in this 
disorder (Perlis et al., 2005). According to these authors, because insomnia symptoms will 
naturally vary across time, the cooccurrence of better sleep and placebo intake represents a 
strong reinforcement that could in part be responsible for the observation that placebo 
response rates increase over time. RLS is associated with insomnia and possibly mood 
disturbances (Picchietti and Winkelman, 2005) and its severity exhibits day-to-day variations. 
Although in our meta-analysis the placebo (and treatment) effect for sleep measures was 
considerably smaller than the effect for RLS severity, the association with sleep and mood 
disturbances may predispose subjects with RLS to the occurrence of a placebo response. 
Research on the placebo effect in depression, however, has also shown that response to 
both treatment and placebo during pharmacological (Benedetti et al., 2005) and cognitive-
behavioural therapy (Mayberg et al., 2000) closely matches the active treatment response 
that the placebo was designed to stimulate (Lidstone and Stoessl, 2007). This would rather 
point to the involvement of the opioid or dopamine system in the placebo response in RLS.  
Apart from the general limitations inherent to meta-analyses (Lyman and Kuderer, 2005) 
there are specific methodological issues to mention regarding our present study. First, our 
data basis is limited insofar as we identified 60 controlled trials but could only include 36. 
Even for these included trials, not all potentially available effect sizes could be extracted due 
to the data not being reported in an appropriate form. Given that a more detailed reporting 
would be more likely in the case of significant treatment effects, i.e. larger treatment-placebo 
differences, our present results could even be an underestimation of the magnitude of the 
placebo effect. A second issue pertains to the choice of the effect size measure. For the 
present analysis, we standardized the change from baseline to endpoint by the standard 
deviation at baseline. Thus, all other parameters being equal, the effect size will be larger if 
the standard deviation is smaller. If an outcome measure is also used as an inclusion 
criterion, a range and thus variance restriction is to be expected, effect sizes will be larger 
and regression to the mean is promoted. This pertains to the IRLS scale for which a 
minimum value of 10 or 15 was generally required. Finally, we included trials conducted 
within the last 25 years. While the aim was to guarantee the completeness of the data basis, 
there was also a notable change in methodology across this large period of time. Standards 
for treatment trials have changed in terms of design, duration and sample size. In addition, 
significant research progresses such as the development of the IRLS scale are reflected by 
the fact that this scale was the primary endpoint in almost all newer studies. For this reason, 
the use of meta-regression to explore the influence of potential moderators of the placebo 
effect was restricted to only two outcome domains and even their results must be treated 
with appropriate caution. Thus, the present analysis cannot claim to provide any insights into 
the role of possible moderators of the placebo effect.  
This meta-analysis has several implications for the planning of both clinical RLS treatment 
studies and basic research programmes. RLS treatment studies have to reckon with a 
substantial placebo effect that increases with study duration. Thus, any long-term controlled 
trial should include a larger number of subjects into the trial. The present meta-analysis can 
only serve as a starting point for research into the nature of the placebo effect in RLS. To 
explore potential moderators and predictors of the placebo effect, more detailed data and 
preferably an individual patient data meta-analysis is needed, which, however, requires the 
cooperation of the respective drug companies to share their data. Potential moderator 
variables that could influence the placebo response are gender and age, the fact of whether 
subjects are drug-naïve or pre-treated or the presence of associated symptoms or 
comorbidities.  
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A further promising area of research would be the imaging of the opioid and dopamine 
systems in RLS in relation to the placebo response. So far, these research projects have 
been restricted to subjects with PD (de la Fuente-Fernández et al., 2001, 2002) and to 
subjects with pain disorders or experimentally induced pain (Colloca and Benedetti, 2005). 
Here, RLS offers the unique possibility to study both systems in the same group of subjects 
and may help to disentangle their respective contributions to the placebo effect. Indeed, the 
multitude of subjective and objective outcome measures used in assessing treatment 
efficacy in RLS, the association with sleep and mood disorders, the occurrence of symptoms 
both consciously experienced and not accessible for the subject, together with the 
responsiveness to dopaminergic as well as opioidergic agents, make RLS a model disease 
to study the placebo effect systematically. Finally, one necessary research project must be 
the inclusion of a no-treatment control group in a future trial. Without such data there is no 
way to differentiate between the natural course of the disease as opposed to the placebo 
effect. In summary, placebo treatment has a strong impact on outcome measures in RLS 
treatment studies, which may not only point to promising research avenues but may also 
challenge us to incorporate the therapeutic placebo effect into clinical practice. 
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Appendix 
Calculation of effect sizes and variances followed the general outline given by Morris and 
DeShon (2002). Effect sizes (ES) were computed from means and standard deviations as 
ES = (Mb - Me)/(SDb) with Mb the mean at baseline, Me the mean at endpoint and SDb the 
standard deviation at baseline. In a minority of cases only the standard deviation of the 
difference between baseline and endpoint was available. In that case, the effect size in the 
change score metric ESdiff = (Mb - Me)/(SDdiff) was transformed into the raw score metric ES = 
ESdiff [2 (1 - r)]1/2 with SDdiff the standard deviation of difference scores and r the correlation 
between baseline and endpoint. All effect sizes were corrected for small sample bias 
following Hedges (1982). The sampling variance of the effect size was computed as Ves = 
[2(1 - r)/n][(n - 1)/(n - 3)][1 + (n/2 (1 - r)) ESg2] - ESg2/c(df)2 with n the number of paired 
observations, ESg the population effect sizes, and c(df) the bias function c(df) = 1 - [3/(4 df - 
1)] with df = n - 1. The correlation between baseline and endpoint was computed from 
standard deviations according to r = (SDb2+SDe2+SDdiff2)/(2 SDb SDe) with SDe the standard 
deviation at the end of the trial.  
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Studies contributing to the meta-analysis  
Studies used to compute correlations 
RLS severity: Montagna et al. (1984), Boghen et al. (1986), Walters et al. (1993), 
Trenkwalder et al. (2004), Stiasny-Kolster et al. (2004b), Bogan et al. (2006), Oertel et al. 
(2006b), GlaxoSmithKline (2006b). 
Subjective sleep parameters: Montagna et al. (1984), Bogan et al. (2006), Oertel et al. 
(2006b). 
Polysomnographic sleep parameters: Walters et al. (1988), Walters et al. (1993). 
PLMS index: Walters et al. (1988), Walters et al. (1993), Bogan et al. (2006). 
Daytime functioning: Walters et al. (1988), Bogan et al. (2006). 
 
Response rates 
CGI: Beneš and TULIR study group (2005), Bogan et al. (2006), Garcia-Borreguero et al. 
(2007), GlaxoSmithKline (2005d), GlaxoSmithKline (2006a), Inoue et al. (2006), Kushida et 
al. (2006), Kushida and Tolson (2006), Oertel et al. (2005), Oertel et al. (2006a), Oertel et al. 
(2006b), Partinen et al. 2006), Stiasny-Kolster et al. 2004b), Trenkwalder et al. (2004), 
Walters et al. (2004), Winkelman et al. (2006), XenoPort (2006). 
Other: IRLS: Garcia-Borreguero et al. (2002), Physician-rating: Boghen et al. (1986), 
Lundvall et al. (1983), Self-made RLS symptom scale: Thorp et al. (2001), No RLS ‘attacks’: 
Telstad et al. (1984), Wish to continue: van Dijk et al. 1991), Different scales: Kohnen et al. 
(2004). 
Multiple time points: Telstad et al. (1984), Walters et al. (2004), GlaxoSmithKline (2005a), 
Winkelman et al. 2006), GlaxoSmithKline (2006a), GlaxoSmithKline (2006b), Oertel et al. 
(2006b), Bogan et al. (2006). 
 
IRLS and other RLS scores 
IRLS: Adler et al. (2004), Trenkwalder et al. (2004), Walters et al. (2004), Stiasny-Kolster et 
al. (2004a), Stiasny-Kolster et al. (2004b), Kelly and Mistry (2005), Oertel et al. (2005), 
GlaxoSmithKline (2006b), GlaxoSmithKline (2005d), Bogan et al. (2006), Partinen et al. 
(2006), Winkelman et al. (2006), Oertel et al. (2006a), Oertel et al. (2006b). 
IRLS and other scales: Stiasny-Kolster et al. (2004a), Stiasny-Kolster et al. (2004b), Oertel et 
al. (2006a), Oertel et al. (2006b). 
Other scales: RLS-6 scales: Stiasny-Kolster et al. (2004a), Stiasny-Kolster et al. (2004b), 
Oertel et al. (2006a), Visual analogue scales: Oertel et al. (2006b), CGI severity item: Wetter 
et al. (1999), Number of RLS ‘attacks’: Telstad et al. (1984), Diaries: Montagna et al. (1984), 
Walters et al. (1993), Montplaisir et al. (1999), Self-made RLS scores: Boghen et al. (1986), 
Wagner et al. (1996), Beneš et al. (1999), Wetter et al. (1999). 
Multiple time points: Trenkwalder et al. (2004), Walters et al. (2004), Bogan et al. (2006), 
GlaxoSmithKline (2006b). 
 
Subjective sleep parameters 
Sleep quality: Medical Outcome Study Sleep Scale: Allen et al. (2004; GlaxoSmithKline 
(2005b), GlaxoSmithKline (2005c), Bogan et al. (2006), GlaxoSmithKline (2006a), 
GlaxoSmithKline (2006b), Schlaffragebogen A: Beneš et al. (1999), Wetter et al. (1999), 
Oertel et al. (2006a; RLS-6 item: Stiasny-Kolster et al. (2004a), Visual analogue scale: Oertel 
et al. (2006b), Diary: Boghen et al. (1986). 
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Subjective sleep duration: Medical Outcome Study Sleep Scale: Allen et al. (2004), 
GlaxoSmithKline (2005b), GlaxoSmithKline (2005c), Bogan et al. (2006), GlaxoSmithKline 
(2006a), GlaxoSmithKline (2006b), Diary: Benes› et al. (1999). 
 
Polysomnographic sleep parameters 
Total sleep time: Walters et al. (s1988), Wagner et al. (1996), Allen et al. (2004), Eisensehr 
et al. (2004), Oertel et al. (2006a). 
Sleep efficiency: Walters et al. (1988), Walters et al. (1993), Wagner et al. (1996), Allen et al. 
(2004), Eisensehr et al. (2004), Oertel et al. (2006a). 
 
PLMS 
Walters et al. (1988), Montplaisir et al. (1996), Walters et al. (1993), Wagner et al. (1996), 
Benes› et al. (1999), Montplaisir et al. (1999), Allen et al. (2004), Eisensehr et al. (2004), 
Polo et al. (2005), Bogan et al. (2006), GlaxoSmithKline (2006a), Oertel et al. (2006a), 
GlaxoSmithKline (2006b), Garcia-Borreguero et al. (2007). 
 
Daytime functioning 
Sleepiness: Medical Outcome Study Sleep Scale: Allen et al. (2004), GlaxoSmithKline 
(2005b), GlaxoSmithKline (2005c), Bogan et al. (2006), GlaxoSmithKline (2006a), 
GlaxoSmithKline (2006b), Epworth Sleepiness Scale: Adler et al. (2004), Stiasny-Kolster et 
al. (2004b), Winkelman et al. (2006), Diary: Walters et al. (1993), Wagner et al. (1996), RLS-
6: Oertel et al. (2006a), IRLS: Oertel et al. (2006b). 
Quality of life: RLS-Quality of Life Questionnaire: Walters et al. (2004), GlaxoSmithKline 
(2005b), GlaxoSmithKline (2005d), Bogan et al. (2006), Winkelman et al. (2006), 
GlaxoSmithKline (2006a), German RLS quality of life: Oertel et al. (2006a). 
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Supplementary material 
 
Supplement 1. Resources used for search 
 
Ressource   
Electronic databases URL Retrieved 
PubMed http://www.ncbi.nlm.nih.gov/entrez/query.fcgi 53 
Cochrane Library http://www3.interscience.wiley.com/cgi-
bin/mrwhome/106568753/HOME 
5 
   
Handsearching of abstract 
books  
Years  
Sleep  2002-2006 3 
Journal of Sleep Research  2002, 2004, 2006 0 
Sleep Medicine  2005, 2007 3 
Neurology  2002-2006 1 
Annals of Neurology 2002-2006 1 
European Journal of Neurology  2003-2006 1 
Journal of Neurology  2002-2006 0 
Movement Disorder  2002-2006 4 
   
Internet ressources URL  
PhRMA Clinical Study 
Results  
www.clinicalstudyresults.org 0 
IFPMA Clinical Trial Results  http://www.ifpma.org/clinicaltrials.html 0 
GlaxoSmithKline Clinical Trial 
Register 
http://ctr.gsk.co.uk/Summary/ropinirole/studylist.a
sp 
6 
Boehringer Ingelheim Trial Results  http://trials.boehringer-
ingelheim.com/Trial_Results/index.jsp 
0 
Lilly clinical trial results http://www.lillytrials.com/results/results_by_ta.htm
l 
0 
Roche http://www.roche-trials.com/results.html 0 
XenoPort http://www.xenoport.com/assets/pdf/ 2 
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Supplement 2  
Investigating significant between-study heterogeneity with a priori planned subgroup 
analysis. Only subgroups with five or more trials are listed. 
 
Outcome/Subgroup n Q df p I2 [CI]
Response rates 24 269.46 23 < 0.0001 91.6% [89% – 94%]
Parallel-group trials 18 59.45 17 < 0.0001 71.4% [54% – 82%]
Cross-over trials 6 55.94 5 < 0.0001 91.1% [83% – 95%]
Study duration = 84 days 8 14.42 7 0.0441 51.5% [0% – 78%]
Study duration < 84 days 16 152.09 15 < 0.0001 90.1% [86% – 93%]
Study duration ≤ 30 days 7 79.71 6 < 0.0001 92.5% [87% – 96%]
Study duration ≥ 35 days 17 74.8 16 < 0.0001 78.6% [66% – 86%]
Group allocation 1:1 16 237.48 15 < 0.0001 93.7% [91% – 95%]
Group allocation 1: >1 8 13.93 7 0.0525 49.7% [0% – 78%]
Idiopathic RLS 16 43.19 15 0.0001 65.3% [41% – 80%]
Dopaminergic drug 16 42.53 15  0.0002 64.7% [40% – 79%]
Non-dopaminergic drug 8 78.82 7 < 0.0001 91.1% [85% – 95%]
Only CGI response rate 17 34.71 16 0.0044 53.9% [20% – 73%]
Other response rates 7 62.3 6 < 0.0001 90.4% [83% – 95%]
    
IRLS 14 118.05 13 < 0.0001 89.0% [83% – 93%]
Parallel-group trials 13 95.78 12 < 0.0001 87.5% [80% – 92%]
Study duration = 84 days 6 52.53 5 < 0.0001 90.5% [82% – 95%]
Study duration < 84 days 8 25.04 7 0.0007 72.0% [43% – 86%]
Study duration ≥ 35 days 11 93.46 10 < 0.0001 89.3% [83% – 93%]
Group allocation 1:1 8 100.75 7 < 0.0001 93.1% [89% – 96%]
Group allocation 1: >1 6 9.87 5 0.0757 49.4% [0% – 80%]
    
RLS scores 12 44.48 11 < 0.0001 75.3% [57% – 86%]
Parallel-group trials 5 30.80 4 < 0.0001 87.0% [72% – 94%]
Cross-over trials 7 1.92 6 0.9270 0% [0% – 9%]
Study duration ≤ 30 days 8 4.64 7 0.7035 0% [0% – 51%]
Group allocation 1:1 9 42.34 8 < 0.0001 81.1% [65% – 90%]
Dopaminergic drug 7 12.17 6 0.0583 50.7% [0% – 79%]
Non-dopaminergic drug 5 11.10 4 0.0255 64.0% [5% – 86%]
    
Sleep quality 12 37.55 11 < 0.0001 70.7% [47% – 84%]
Parallel-group trials 9 30.12 8  0.0002 73.4% [48% – 86%]
Study duration = 84 days 6 24.74 5  0.0002 79.8% [56% – 91%]
Study duration < 84 days 6 12.00 5 0.0348 58.3% [0% – 83%]
Study duration ≥ 35 days 9 30.12 8 0.0002 73.4% [48% – 86%]
Group allocation 1:1 10 37.12 9 < 0.0001 75.8% [55% – 87%]
Dopaminergic drug 11 37.44 10 < 0.0001 73.3% [51% – 85%]
    
Subjective Sleep Duration 7 27.49 6 < 0.0001 78.2% [55% – 90%]
Parallel-group trials 6 26.89 5 < 0.0001 81.4% [60% – 91%]
    
Total Sleep Time 5 12.56 4 0.0136 68.2% [18% – 88%]
    
Sleep Efficiency 6 7.96 5 0.1582 37.2% [0% - 75%]
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Table continued    
Periodic Leg Movements 14 14.53 13 0.3375 10.5% [0% – 49%]
    
Quality of Life 7 121.24 6 < 0.0001 95.1% [92% – 97%]
Parallel-group trials 6 97.88 5 < 0.0001 94.9% [91% – 97%]
Group allocation 1:1 6 120.41 5 < 0.0001 95.8% [93% – 98%]
    
Sleepiness 13 156.28 12 < 0.0001 92.3% [89% – 95%]
Parallel-group trials 10 142.79 9 < 0.0001 93.7% [90% – 96%]
Study duration = 84 days 7 108.86 6 < 0.0001 94.5% [91% – 97%]
Study duration < 84 days 6 33.59 5 < 0.0001 85.1% [70% – 93%]
Study duration ≥ 35 days 9 141.08 8 < 0.0001 94.3% [91% – 96%]
Group allocation 1:1 11 153.69 10 < 0.0001 93.5% [90% – 96%]
Dopaminergic drug 11 150.53 10 < 0.0001 93.4% [90% – 96%]
MOS somnolence items 6 108.79 5 < 0.0001 95.4% [92% – 97%]
Other sleepiness scales 7 40.08 6 < 0.0001 85.0% [71% – 92%]
CI: confidence interval; RLS: restless legs syndrome; CGI: Clinical Global Impression scale; MOS: 
Medical Outcome Study scale 
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Supplementary Fig 1. [Response rates across all studies in relation to study duration. The size of
circles is proportional to weight of study.] 
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Supplementary Fig 2. [Meta-analysis of standardized repeated-measures effect sizes for the placebo 
effect in measures of daytime sleepiness (CO: cross-over trial, PG: parallel-group trial, CI: confidence 
interval)]. 
 
Supplementary Fig 3. [Meta-analysis of standardized repeated-measures effect sizes for the placebo 
effect in quality of life (CO: cross-over trial, PG: parallel-group trial, CI: confidence interval)]. 
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Material available upon request 
Excluded studies: 
Study Reason for Exclusion 
Saletu et al. 2000a Single-blind study  
Saletu et al. 2001 Single-blind study 
Saletu et al. 2002 Single-blind study 
Zucconi et al. 2003 Single-blind study 
  
Tagaya et al. 2002 Same study as Wetter et al. 1999 
Brodeur et al. 1988 Same study as Montplaisir et al. 1996 
Larsen et al. 1985 Same study as Telstad et al. 1984 
Brenning 1971 Sames study as Brenning 1969 
Saletu et al. 2000b Same study as Saletu et al. 2000a 
  
Ausserwinkler & Schmidt 1989 Non-randomised study 
Kaplan et al. 1993 Not all subjects had RLS 
Reuter et al. 1999 Only a single subject 
Hening et al. 1986 Naloxone placebo, concomitant medication 
von Scheele 1986 Inadequate study design 
  
Earley et al. 1998 No data extraction possible 
Pieta et al. 1998 No data extraction possible 
Akpinar 1987 No data extraction possible 
Saletu et al. 2003 No data extraction possible 
Walker et al. 1996 No data extraction possible 
Trenkwalder et al. 1995 No data extraction possible 
Winkelman & Johnston 2006 No data extraction possible 
Leissner et al. 2004 No data extraction possible 
Wang et al. 2006 No data extraction possible 
Quinn and Biber 2006 No data extraction possible 
Ulfberg et al. 2007 No data extraction possible 
Hornyak et al. 2006 No data extraction possible 
  
Sloand et al. 2004 Concomitant RLS medication 
Davis et al. 2000 Concomitant RLS medication 
Collado-Seidel et al. 1999 Concomitant RLS medication 
Trenkwalder et al. 2004 Single-blind placebo baseline 
  
Bliwise et al. 2005 Withdrawal design 
Montplaisir et al. 2006 Withdrawal design 
Trenkwalder et al. 2006 Withdrawal design 
Beneš 2006 Withdrawal design 
  
Brenning 1969 Questionable diagnosis of RLS 
Hürlimann 1974 Questionable diagnosis of RLS 
Christiansen 1970 Questionable diagnosis of RLS 
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IV. Prevalence of the restless legs syndrome in transsexual 
patients: the hormonal hypothesis revisited 
This is a pre-copy-editing, author-produced PDF of an article accepted for publication in 
Journal of Neurology following peer review. The original publication [Prevalence of the 
restless legs syndrome in transsexual patients: the hormonal hypothesis revisited. Stephany 
Fulda, Günther K. Stalla, Thomas C. Wetter. Journal of Neurology 2007; DOI 
10.1007/100415-007-0624-6] is available at: www.springerlink.com 
 
Sirs: Epidemiological studies that have employed established diagnostic criteria1 show a 
markedly higher prevalence of the restless legs syndrome (RLS) in women2,3. The increased 
risk for RLS in females is related to the number of pregnancies3. In addition, around 25% of 
females will experience RLS symptoms during pregnancy with the highest prevalence during 
the last trimester8,9,11. Iron requirements during pregnancy are increased and may play a role 
in the etiology of RLS8. However, a hormonal hypothesis regarding the incidence of RLS 
during pregnancy has already been postulated by Ekbom5, and a recent study6 has shown 
that pregnant women with RLS had significantly higher estradiol levels only during late-term 
pregnancy compared to those without RLS.   
We therefore explored the prevalence of RLS in a group of transsexual patients treated with 
either testosterone or estrogens to elucidate the role of gender and steroid hormones as a 
risk factor for RLS. The study was approved by the local ethic committee. Questionnaires 
were mailed to 288 transsexual patients registered at the outpatient clinic for endocrinology 
at the Max Planck Institute of Psychiatry. Accompanying the questionnaires was a letter
                                                 
 Fulda S, Stalla GK, Wetter TC. Prevalence of the restless legs syndrome in transsexual patients: the 
hormonal hypothesis revisited. Journal of Neurology 2007; 254: 1748-1749. 
Fig. 1. Study design and response rates. (RLS = restless legs syndrome) 
RLS in transsexual patients 
 
Table 1. Characteristics of participants (mean ± standard deviation) 
 Estrogen- 
treated subjects 
Testosterone-
treated 
subjects 
 
 N = 30 N = 43 Test statistica, p 
 
Age, years 
 
46.36 ± 7.10 
 
31.93  ±  7.98 
 
t = 7.95, p < 0.001 
Age range, years 31 - 61 21-54  
BMI 24.61 ± 3.35 23.58 ± 3.47 Fb = 3.16, p = 0.080 
Duration of hormone treatment, 
months 
74.93 ± 75.58 75.88 ± 56.51 Uc = 597, p = 0.594 
PSQI 5.16 ± 2.39 
(n = 25) 
5.62 ± 4.29 
(n = 35) 
Fb = 0.79, p = 0.378 
ESS 7.44 ± 4.16 
(n = 29) 
7.62  ±  4.07 
(n = 42) 
Fb = 0.01, p = 0.936 
Sleep onset latency, mine 15.13 ± 12.92 
(n = 30) 
18.53 ± 16.76 
(n = 43) 
Fb = 0.27, p = 0.871 
Sleep duration, hours 7.42 ± 2.09 
(n = 29) 
7.48 ± 2.11 
(n = 41) 
Fb = 0.21, p = 0.886 
All 4 RLS symptoms (n, %) 6 (20.0 %) 4 (9.3%) pd = 0.300 
PSQI = Pittsburgh Sleep Quality Index; ESS = Epworth Sleepiness Scale 
a Because of missing data for some of the parameters a multivariate approach to control the overall 
type-I error rate was not feasible. 
b Analysis of variance F-tests included age as a covariate 
c Mann-Whitney U test 
d Fisher’s Exact Test 
e due to substantial skewness, sleep onset latency was log-transformed before being entered into the 
analysis 
 
 
 
explaining the purpose of the study and assuring anonymity to all participants. The returning 
of the questionnaires was regarded to signify informed consent. Basic information was 
ascertained concerning age, weight, height, co-morbidities, intake of medication and 
hormonal treatment. Sleep quality (Pittsburgh Sleep Quality index4) and daytime sleepiness 
(Epworth Sleepiness Scale7 (ESS)) was assessed. Subjects were asked for the four cardinal 
symptoms of RLS1, a rating of symptom severity and their first occurrence (lifetime). 
Differences between the two groups were explored with univariate analysis of variance with 
age as a covariate due to the significant age difference between the two groups (t-test). Non-
parametric tests (Mann-Whitney U-Test, Fisher’s Exact Test) were applied for non-normally 
distributed variables and frequencies.  
Eigthy-one questionnaires were returned and 73 subjects were currently treated with 
testosterone or estrogens (Figure 1). All 43 testosterone-treated subjects were female-to-
male transsexual patients while the estrogen-treated group (n = 30) included one 
hermaphrodite beside the female-to-male transsexual patients. The main results are given in 
Table 1. Twenty percent of the estrogen-treated subjects affirmed all four RLS criteria 
compared to 9.3% of the testosterone-treated subjects (p = 0.30). Because the testosterone-
treated subjects were younger on average than the estrogen-treated subjects we repeated 
the analysis considering only the 22 testosterone-treated participants within the age range of 
the estrogen-treated participants. The difference in prevalence (20.0% vs. 4.5%) became 
more pronounced but still did not reach statistical significance (p = 0.22).  In half of the ten 
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subjects with RLS, symptoms started after hormonal treatment began. None of them was 
treated for RLS. Two participants took medication that could have aggravated RLS 
(venlafaxine, 75 mg (one subject) and flupentixol, 10 mg (one subject)), however, these two 
subjects did not report restless legs symptoms. 
Overall, we found a higher, although statistically not significant, prevalence in estrogen-
treated transsexuals as compared to testosterone-treated subjects. It is most likely that the 
study was underpowered regarding the number of subjects. Although we contacted nearly 
300 persons, ultimately a considerable lower number replied. For one, it is known that there 
is a limited accessibility for this target population10, and this might account for the 35% of 
subjects we were unable reach by mail. Secondly, we assured subjects’ anonymity, and thus 
we were not able to re-contact subjects to achieve a higher response rate and to gather more 
detailed data and follow-up of the affected individuals. Finally, we explored the presence of 
restless legs symptoms at the time of investigation and may thus have missed those subjects 
in whom hormonal treatment may have induced a transient RLS. Despite these constraints, 
this pilot study suggests that estrogens may play a role in the development of RLS. Further 
studies, however, are needed to replicated and extend this findings and to assess the 
prevalence of RLS in a larger number of transsexual patients.  
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V. Genome-wide association study of restless legs 
syndrome identifies common variants in three genomic 
regions 
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Stephanie Hauk, Claudia Trenkwalder, Alexander Zimprich, Karian Stiasny-Kolster, 
Wolfgang Oertel, Cornelius G. Bachmann, Walter Paulus, Ines Peglau, Ilonka Eisensehr, 
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2007; DOI 10.1038/ng2099] is available at:  
 www.nature.com/ng/journal/v39/n9/abs/ng2099.html 
 
Abstract 
Restless legs syndrome (RLS) is a frequent neurological disorder characterized by an 
imperative urge to move the legs during night, unpleasant sensation in the lower limbs, 
disturbed sleep and increased cardiovascular morbidity. In a genome-wide association study 
we found highly significant associations between RLS and intronic variants in the homeobox 
gene MEIS1, the BTBD9 gene encoding a BTB(POZ) domain as well as variants in a third 
locus containing the genes encoding mitogen-activated protein kinase MAP2K5 and the 
transcription factor LBXCOR1 on chromosomes 2p, 6p and 15q, respectively. Two 
independent replications confirmed these association signals. Each genetic variant was 
associated with a more than 50% increase in risk for RLS, with the combined allelic variants 
conferring more than half of the risk. MEIS1 has been implicated in limb development, raising 
the possibility that RLS has components of a developmental disorder. 
 
 
 
Nightwalkers, as individuals with RLS call themselves, are forced to move their legs during 
periods of rest especially in the evening and night to relieve uncomfortable or painful 
sensations in the deep calf1. This diurnal variation leads to impaired sleep onset, and the 
periodic leg movements during sleep in the majority of patients contribute to sleep disruption 
and a reduced quality of life as a major consequence2. There are recognized secondary 
forms of RLS such as in iron deficiency, pregnancy and end-stage renal disease and 
associated morbidity such as increased cardiovascular risk2,3. RLS is one of prevalence of up 
to 10% in the elderly in North America and Europe2. Dopaminergic agents originally 
developed for Parkinson’s disease have been used to treat RLS, with an unknown mode of 
action2. Neurophysiological, pharmacological and neuroimaging studies suggest that the 
characteristic symptoms originate in the central nervous system, yet the underlying 
                                                 
 Winkelmann J, Schormaier B, Lichtner P, Ripke S, Xiong L, Jalilzadeh S, Fulda S, Pütz B, Eckstein 
G, Hauk S, Trenkwalder C, Zimprich A, Stiasny-Kolster K, Oertel W, Bachmann CG, Paulus W, Peglau 
I, Eisensehr I, Montplaisir J, Turecki G, Rouleau G, Gieger C, Illig T, Wichmann HE, Holsboer F, 
Müller-Myhsok B, Meitinger T. Genome-wide association study of restless legs syndrome identifies 
common variants in three genomic regions. Nat Genet 2007; 39(8): 1000-1006. 
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neurobiology remains obscure4. A family history of RLS is present in more than 50% of 
affected individuals, and similar figures have been reported for heritability in twin studies5,6. 
Linkage analysis uncovered five loci based on recessive (RLS1) or dominant inheritance 
(RLS2–RLS5), but so far the most common neurological disorders, with an age-dependent 
no causally related sequence variants have been identified5–7. With SNP arrays becoming a 
mature technology, we conducted a genomewide association study (GWAS), typing 500,568 
SNPs in individuals with RLS and in a large control cohort from the general population. 
 
Genome-wide association 
The study design involved an exploratory stage (stage 1) followed by replication in two 
further case-control samples (stages 2a and 2b) (Fig. 1). In stage 1, we performed a GWAS, 
typing cases and controls on a single platform with the Affymetrix 500K Array Set. To enrich 
for risk alleles and minimize phenotypic heterogeneity, we selected subjects with familial RLS 
(n = 401). Controls were selected randomly from a population-based cohort (n = 1,644, from 
the KORA-S3/F3 survey, described previously)8. For statistical analysis, we selected SNPs 
by including only high-quality genotypes to reduce the number of false-positive signals 
(Supplementary Table 1). A total of 236,758 SNPs passed all quality control filters (mean call 
rate = 99.48%). The effect of population stratification was negligible (inflation factor λ = 1.09 
via genomic control)9 (Fig. 2). Eigenvalue-based analysis showed only minimal population 
substructure (Fig. 2). An Armitage trend test uncovered four SNPs with P values < 10–6 (Fig. 
3 and Supplementary Table 2). After correcting for multiple testing, we identified a single 
SNP within MEIS1 that reached genome-wide significance (rs2300478, Pcorrected < 0.0002). 
 
 
Fig. 1. Numbers refer to cases and controls and SNPs genotyped and analyzed. The 13 most
significant SNPs together with neighboring SNPs were replicated in a German ('a') and a Canadian 
('b') case/control sample. Three loci were confirmed in both stage 2 samples of the study. 
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Replication of genome-wide findings  
For stage 2 replication, 13 SNPs passed our inclusion criteria based on P value, location 
within a linkage peak and visual inspection of clustering data. We selected these and 15 
neighboring SNPs for replication. They mapped to six discernible regions. Of these 28 SNPs, 
25 were successfully genotyped in stage 2a and 24 in stage 2b (Supplementary Table 3). 
Individuals in 2a (n = 903, familial or sporadic RLS) had been recruited separately using the 
sampling design of stage 1. Control subjects were selected from KORA-S4 (n = 891).  
In stage 2a, we found nominally significant evidence for association in five regions, of which 
three withstood correction for multiple testing (Fig. 4 and Supplementary Table 4). The first 
region was on 2p, located in a 32-kb linkage disequilibrium (LD) block containing exon 9 of 
MEIS1. Here, two of three SNPs showed significant association (P < 10–11). MEIS1 is a 
member of a family of highly conserved TALE homeobox genes. Heterodimers of MEIS1 with 
PBX and HOX proteins augment the affinity and specificity of DNA binding by HOX proteins10. 
MEIS1 has been found to be overexpressed in acute myeloid leukemia10, and studies in 
Xenopus laevis have shown involvement in neural crest development11. In addition, there are 
several potential links to RLS: during embryonic development, MEIS1 is essential for 
proximo-distal limb formation12, and children with restless legs syndrome are often described 
as having growing pains13. MEIS1 is part of a Hox transcriptional regulatory network that 
specifies spinal motor neuron pool identity and connectivity14. Notably, spinal 
hyperexcitability is an established component in the genesis of periodic leg movements 
found in individuals with RLS15. Specific functions of MEIS1 in postembryonic tissues still 
remain to be established. The protein is known to be expressed in the adult mouse brain in 
Fig. 2. Extent of population stratification. The distribution of expected (under the null hypothesis) 
versus observed χ2 values (all P values obtained in the analysis of sample 1, using Armitage trend test 
with age and sex as covariates) before (blue) and after (red) correction by division with λ. Adherence 
to the diagonal indicates lack of inflation of the statistic. As can be seen in the uncorrected plot, there 
is evidence for a systematic deviation toward higher-than-expected values. After the correction, there 
is nearperfect adherence to the diagonal for most of the values obtained, indicating that the correction 
performed well. 
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cerebellar granule cells, the forebrain and, notably, in dopaminergic neurons of the 
substantia nigra16. 
The second region with significant association was on chromosome 6p, within a 113-kb LD 
block in intron 5 of the BTBD9 gene. All five SNPs tested were significant, four of these with 
P values < 10–5. Little is known about BTBD9 other than that it belongs to the BTB(POZ) 
proteins. BTB stands for broad complex, tramtrack and bric a` brac, genes that in Drosophila 
melanogaster are required for embryonic development, cell fate determination in the eye, 
metamorphosis and pattern formation in the limbs17,18. Functions of BTB(POZ) proteins 
include transcription repression, cytoskeleton regulation, tetramerization and gating of ion 
channels, as well as ubiquitindependent protein degradation17. The modular nature of this 
protein and the universal occurrence of the particular domains of BTBD9 make assignment 
of a specific function difficult at present.  
The third region, defined by seven SNPs tested on 15q, showed significant evidence for 
association, with P < 10–4. This region contains a 48-kb LD block overlapping the 3’ end of 
MAP2K5, a member of the mitogen-activated protein kinase family, and the adjacent 
LBXCOR1 gene. MAPK pathways are conserved from yeast to human and are activated by a 
signaling cascade that mediates the transduction of extracellular signals to cytoplasmic 
nuclear effectors19. MAP2K5 is a specific upstream activator of ERK5, and this pathway is 
activated by oxidative stress, hyperosmolarity and growth factors. In addition, MAP2K5 and 
ERK5 are abundantly expressed in heart and skeletal muscles, and the MAP2K5/ERK5 MAP 
kinase cascade is critical at early stages of muscle cell differentiation19. The possible link 
between RLS risk alleles and known biological functions of the MAP2K5-ERK5 pathway is of 
particular interest, as this pathway is important in neuroprotection of dopaminergic neurons20. 
LBXCOR1 is annotated as being downstream of MAP2K5 and acting as a transcriptional 
corepressor of LBX1. This homeobox gene is critical in the development of sensory the
Fig. 3. Genome-wide association study for RLS susceptibility loci. The analysis compared 393
successfully genotyped RLS cases with 1,602 population-based KORA controls. The x-axis represents
genomic position, and the y-axis shows –log10(P). Thirteen SNPs that passed inclusion criteria for the
replication study of stage 2 are highlighted in bold. Note that the P values of three SNPs on
chromosome 15 are very similar, and these SNPs appear as one single dot. 
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Table 1.  Confirmed association results 
 
 
pathways in the dorsal horn of the spinal cord that relay pain and touch21. Three SNPs within 
PTPRD gene in the chromosome 9 linkage region (RLS3) and one SNP on chromosome 16 
in the A2BP1 gene were nominally significant. 
In stage 2b, we genotyped the same SNPs in affected individuals (n = 255) and controls (n = 
287) from a French-Canadian population. Here, we found nominally significant evidence for 
association in four regions (two SNPs on chromosome 2p, five SNPs on 6p, seven SNPs on 
15q and one SNP on 16p, Supplementary Table 5). The same three regions as in stages 1 
and 2a remained significant after correction for multiple testing. Odds ratios (ORs) and risk 
alleles were very similar to those for stage 2a. Table 1 shows those nine SNPs in the three 
loci confirmed in all three sample sets and in joint analysis withstanding genome-wide 
correction for multiple testing. 
 
Fine mapping, haplotype and risk analysis 
We genotyped tagging SNPs and all known coding and splice-site SNPs for fine mapping in 
the stage 2a samples. This confirmed the candidate regions defined by the explorative phase 
of the study (Fig. 4). Haplotype analysis for MEIS1 delineated a haplotype block (rs3890755 
to rs12469063). A haplotype completely described by allele A (rs6710341) and allele G 
(rs12469063) was more strongly associated than each single SNP in this block (P = 5.87 x 
10–20, OR = 2.75 [95% confidence interval, 2.23–3.41]). This haplotype was also maximally 
associated in the Canadian sample (P = 8.51 x 10–7, OR = 2.36 [1.40–3.97], Fig. 5). For 
SNPs with significant association that were successfully genotyped in all three case-control samples, located in three different 
genomic regions. Genome positions refer to the human March 2006 (hg18) assembly. [MAP2K5/LBXCOR1] denotes an 
intergenic position of the SNP. MAF, minor allele frequency; OR, odds ratio; c.i., confidence interval; Pnom = nominal P value. 
MAF refers to stage 2a data only; OR was calculated using combined data from all stages. P values for stage 1, 2a and 
combined analysis were calculated using logistic regression implementing an Armitage trend test and taking sex and age as 
covariates into account. P values in stage 1 and 2a resulting from this regression were further corrected for population 
stratification by dividing the resulting χ2 by the inflation factor l. aPcorrected = P value corrected for multiple testing using 
Bonferroni’s method, correcting for 236,758 SNPs.  
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BTBD9 and the MAP2K5 and LBXCOR1 region haplotype analysis confirmed the results of 
single-SNP analysis. 
In exploratory analysis, we compared the ORs obtained under the allele dosage model to 
those obtained under the unrestricted model. For MEIS1 and BTBD9, we did not find any 
significant difference between the models tested (MEIS1: P = 0.714; BTBD9: P = 0.913), but 
the allele dosage model was more parsimonious. For the MAP2K5 and LBXCOR1 region, 
the allele dosage model was significantly less likely than the unrestricted model (P = 0.006). 
Estimates pointed to a recessive model. This model was significantly better than the allele 
dosage model (P = 0.009) and not worse than the unrestricted model (P = 0.395). There was 
no difference in effect estimates between samples (Supplementary Table 6).  
In the combined German samples, lower limits of the sequential attributable fraction 
(SAFs)22,23 were estimated at 0.092, 0.303 and 0.079 for MEIS1, BTBD9 and the MAP2K5 
and LBXCOR1 region respectively. Corresponding upper limits (equal to the population 
attributable risk fraction (ARF)) were 0.227, 0.492 and 0.201. In the Canadian sample, the 
lower limits of the SAFs were 0.075, 0.316 and 0.090, respectively, and we estimated the 
upper limits at 0.226, 0.550 and 0.258, respectively.We could not identify any statistical 
interaction between these loci, either in the individual samples or in the combined German or 
combined German-Canadian samples. Overall, although the single ARF and SAF estimates 
may be slightly overestimated, they clearly indicate that the three loci account for a large part 
of the phenotype in the populations studied. We estimated the ARF jointly attributable to the 
three loci at 68.6% in the German population and 74.2% for the Canadian population. 
A comparison of familial versus sporadic cases in the combined stage 1 and 2a data set 
demonstrated virtually indistinguishable ORs for the regions on 6p and 15q. For the region 
on 2p, the risk was higher in familial (rs2300478: OR = 1.82 [1.55–2.14]) than in sporadic 
cases (OR = 1.59 [1.34–1.90]). However, confidence intervals were overlapping with no 
significant difference in allele distributions (P = 0.22, Supplementary Table 7). The familial 
relative risk figures estimated by the risk to siblings λs were 1.13 for MEIS1, 1.02 for BTBD9 
and 1.03 for MAP2K5/LBXCOR1 in the German data set, with almost identical estimates in 
the Canadian data.  
The increasing medical attention to RLS in recent years is matched by our ignorance about 
its underlying molecular basis. The genetic heterogeneity of RLS has made linkage studies 
notoriously difficult and favors association approaches. In agreement with power calculations, 
an initial genome-wide screen for common variants in 400 cases and 1,600 controls enabled 
us to detect risk alleles with odds ratios > 1.5. Sample size in the replicate was twice as high 
as in the initial GWAS and provided unequivocal evidence for the signals. The effects were 
strong enough that a second replication in a small independent sample from Canada also 
yielded significant signals for all three regions. A particular feature of our study design is the 
use of a control group from the general population. This provided us with very accurate 
estimates of the genotype frequencies and it avoided any bias to which a disease-negative 
population is prone. 
The identification of significant signals in genes that have not been considered candidates 
from previous biological knowledge is a recurring theme in GWASs24. The current knowledge 
about MEIS1, BTBD9, MAP2K5 and LBXCOR1 opens new avenues of RLS research, and 
the involvement of developmental genes challenges us to rethink our basic concept of this 
widespread disease. 
A major proportion of the risk for RLS is explained by variants in the loci identified. We could 
not derive any different contributions from any of these loci to familial versus sporadic RLS. 
The associated variants all convey very low familial relative risk (λs < 1.15 in all cases). The 
lack of positive results within the known linkage regions does not argue against the validity of 
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Fig. 4. Pairwise linkage 
disequilibrium diagrams for three 
RLS-associated loci. (a) MEIS1. 
(b) BTBD9. (c) Region of 
MAP2K5 and LBXCOR1. The P 
values based on the stage 1 
Affymetrix data clearly delineate 
the regions of interest within a 
single LD block in the limits of 
the transcribed genomic unit for 
MEIS1 and three joint LD blocks 
in BTBD9. For the region of 
MAP2K5 and LBXCOR1, the 
region of interest is limited to a 
single LD block beginning in the 
transcribed unit of MAP2K5 and 
ending in the transcribed unit of 
LBXCOR1. Pairwise LD, 
measured as D’, was calculated 
from the stage 1 control data set 
using the methods of Gabriel as 
implemented in Haploview. 
Shading represents the 
magnitude and significance of 
pairwise LD, with a white-to-red 
gradient reflecting lower to 
higher LD values. Stage 1 
Affymetrix SNPs are indicated by 
red squares, replication SNPs 
(Stage 2a) by black circles and 
fine mapping SNPs (Stage 2a) 
by blue triangles. x-axis shows 
genomic position, and y-axis 
shows –log10(P). Transcriptional 
units are indicated by black 
arrows, with exons depicted as 
black bars. 
 
 
 
 
 
 
Genetics of RLS 
 
 66  6  
the linkage results. The nominally significant signals detected in the RLS3 linkage region 
might indicate an allelic series of variants conferring weak and strong effects within the same 
gene. 
This study is not exhaustive in identifying genetic factors contributing to RLS, and further 
investigations will provide a better picture of what constitutes the genetic architecture of the 
complex phenotype of restless legs syndrome. Future studies should investigate 
endophenotypes or secondary RLS cases, which might show alternative signal patterns. An 
interesting question is also whether the loci identified have a role in other 
dopaminergicdisorders such as Parkinson’s disease or in other associated disorders such as 
attention deficit hyperactivity disorder or sleep disorders. Further experimental advances 
might include features such as higher sample numbers in the exploratory stage, higher SNP 
density, modification of clustering algorithms25, inclusion of lower frequency polymorphisms, 
investigation of copy number changes and use of lower statistical thresholds using a priori 
information. 
 
METHODS 
Study population and phenotype assessment.  
Cases of stages 1 and 2a were of European descent and were diagnosed according to 
standard criteria2 in a personal interview. Familial RLS was defined by at least one affected 
first-degree relative. We excluded subjects with secondary RLS due to uremia, dialysis and 
iron deficiency. 
Controls of stage 1 and 2a were of European descent and from the KORA S3/ F3 and S4 
surveys, representative of the general population. KORA procedures have been described8. 
For stage 1, we included 1,644 subjects from S3/F3, ages 35–84 years, and for stage 2a, 
Fig. 5. A haplotype consisting of six SNPs (of which rs6710341 and rs12469063 fully tagged the risk
haplotype) is associated with RLS with odds ratios of 2.75 and 2.36 in the stage 2a and 2b samples,
respectively. Haplotype frequencies for all haplotypes occurring with these six SNPs are based on 
cases and controls jointly and are given for cases and controls separately for the risk haplotype. For
the Canadian sample, the frequencies are given in brackets and are based on the two tagging SNPs. 
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891 age- and sex-matched subjects from S4. In 2a, 102 affected individuals were outside the 
age range of KORA and were matched to the next age group. 
Affected individuals and controls of stage 2b were of French-Canadian ancestry. Affected 
individuals (n = 255) were diagnosed according to standard criteria2, and polysomnography 
was performed in 156 subjects; of those, 82.1% (n = 128) showed significant periodic leg 
movements during sleep. Controls were recruited from the general population (n = 287). 
Secondary cases were excluded. 
Studies were performed according to the declaration of Helsinki and approved by institutional 
review boards in Germany, Austria, and Canada. Written informed consent was obtained 
from participants. For demographic data of successfully genotyped samples, see 
Supplementary Table 8.  
 
Genome-wide assays, SNP genotyping and quality control.  
Stage 1 genotyping was performed using the Affymetrix 500K Array Set. Genotypes were 
determined using the BRLMM algorithm with cases and controls undergoing a joint cluster 
analysis. From 500,568 SNPs, a total of 236,758 were selected for subsequent analyses 
based on stringent quality control criteria. Exclusion criteria were call rate < 98% (n = 
146,297), minor allele frequency (MAF) < 10% (n = 151,583), deviations from HWE (P < 
0.00001, n = 22,536) and low number of heterozygotes (<10, n = 33,122). 14,069 SNPs were 
monomorphic. For a detailed breakdown, see Supplementary Table 1.  
For the 13 SNPs passing the inclusion criteria for genotyping in stages 2, visual inspection of 
clustering was performed using the Affymetrix SNP Signaling Tool 1.0.0.12. All clusters 
passed this test. To validate the stage 1 experiment, we genotyped 15 SNPs in 400 samples 
on another platform (Sequenom MassArray system) with a genotype discordance rate of 
0.2%.  
Stage 2 and fine-scale mapping were performed using MALDI-TOF mass spectrometry on a 
Sequenom system (Autoflex HT and SpectroTYPER RT 3.4 analysis software). Assays were 
designed using AssayDesign 3.1.2.2 with iPLEX Gold chemistry default parameters. 
Supplementary Table 9 lists oligonucleotide sequences of replication and fine mapping. 
SNP quality control criteria leading to exclusion were call rate < 97%, MAF < 10% and P < 
0.001 for deviations from HWE in controls. This resulted in an exclusion of one SNP 
(rs2110974) in stage 2a, two SNPs (rs2110974, rs7881785) in stage 2b and 51 SNPs in fine 
mapping. All coding SNPs were monomorphic. A total of 28 affected individuals and 55 
controls in stage 2a and 44 affected individuals and 46 controls in stage 2b were excluded 
owing to low call rate (< 90%) of all SNPs within a single DNA sample.  
 
SNP selection for stage 2.  
We used the following inclusion criteria: (i) P < 10–6 in stage 1 analysis (four SNPs); (ii) P ≤ 
10–5 with two neighboring SNPs (± 100 kb) with P ≤ 10–3 (eight SNPs); (iii) P ≤ 10–4 for SNPs 
within described linkage peaks (one SNP in RLS3). For these 13 SNPs, we chose 15 
additional neighboring SNPs based on LD structure for genotyping in the replication samples 
2a and 2b (Supplementary Table 3). 
 
SNP selection for fine mapping.  
SNPs in the coding regions and 10 kb of flanking sequences were selected using the Tagger 
algorithm (r2 = 0.8) implemented in HAPLOVIEW 3.3.2 (ref. 26). In addition, all coding-region 
SNPs and splice-site SNPs were included. This led to 41 SNPs on chromosome 2p (38 
tagging, 1 synonymous and 2 nonsynonymous), 77 SNPs on chromosome 6p (tagging only) 
Genetics of RLS 
 
 68  68 
and 46 SNPs on chromosome 15q (37 tagging, 1 synonymous, 4 nonsynonymous, 2 splice 
site, 2 frameshift coding). In total, 164 SNPs were selected, of which 163 were converted into 
genotyping assays, and 103 with a MAF >10% were analyzed. 
 
Analysis of genetic effects.  
To test and correct for possible population stratification, we performed an EIGENSOFT27,28 
analysis. We used a random sample of 16,000 SNPs passing the quality criteria for the stage 
1 sample and allowed for ten rounds of outlier removal. In the first six rounds, a total of 50 
outliers (8 cases and 42 controls) were removed, with none removed in the remaining rounds. 
To assess stratification, we compared the expected distribution of P values for association 
versus the expected χ 2 distribution with one degree of freedom29. We compared the 
empirically observed mean of the lower 90% of the distribution of the statistics observed and 
divided it by its expectation9. This led to an inflation factor (λ) of 1.09 (Fig. 2).  
We performed logistic regression analysis coding the number of minor alleles as the 
dependent variables, thus implementing Armitage’s trend test, including age and sex as 
covariates and allowing for interactions between age, sex and the number of alleles. Odds 
ratios and confidence interval limits were obtained through logistic regression analysis. The  
χ2 values resulting from these analyses (stage 1, 2a and fine mapping) were divided by λ, 
assuming similar conditions for both German samples. 
Haplotype analysis was performed using HAPLOVIEW 3.3.2 (refs. 26,29), with the fraction of 
strong LD informative comparisons set at 0.9, and using UNPHASED 3.0.8, which allows the 
incorporation of age and sex as covariates30. Haplotype blocks were delineated using the 
method of Gabriel implemented in HAPLOVIEW26. ORs were obtained using logistic 
regression with age and sex as covariates in the stage 2 samples. χ2 and P values in 2a 
were λ corrected. Differences between familial and sporadic cases were tested using 
Fisher’s exact test. Familial attributable risks were calculated using the power calculator 
described in ref. 22. 
 
Multiple testing.  
Using WG-PERMER, a program for rapid permutation of genome-wide data, preliminary 
analysis showed that P values after Westfall- Young and Bonferroni correction, with the 
number of tests set at the number of SNPs tested (n = 236,758), were in good agreement. 
This may reflect stringent criteria for SNPs to enter the analysis, resulting in low average r2 
values between SNPs. To maintain comparability across results, we show Bonferroni-
corrected P values for stage 1 and the combined analysis. For stages 2a and 2b, we give 
Westfall-Young–corrected P values based on 10,000 permutations, as only a few candidate 
regions were tested with high LD between them, and thus Bonferroni would be conservative. 
 
Power analysis.  
Power analysis for the combined German sample was performed using the Genetic Power 
Calculator (http://pngu.mgh.harvard.edu/ ~purcell/gpc/). The power of any SNP tested with 
MAF ≥ 0.2 and OR ≥ 1.5 (or 1/1.5 or lower) was beyond 90%. The P value used was the P 
value required for a significant result after Bonferroni correction (P = 0.05/236,758 = 2.112 x 
10–7). 
 
Testing the mode of inheritance.  
OR values and likelihoods were obtained using logistic regression analysis with age, sex and 
samples as covariates in the combined stage 1, 2a and 2b samples. Significance testing 
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between models was done using the likelihood ratio test.  
 
Attributable risk fraction.  
To quantify the contribution of these loci to RLS, we estimated the population attributable risk 
fraction (ARF)22 and the sequential attributable fraction (SAF)23. We used the allele dosage 
model for MEIS1 and BTBD9 and the recessive model for MAP2K5 and LBXCOR1 and 
calculated upper and lower limits of SAFs23. For each locus, we used the SNP with the 
lowest P value, aware of the fact that this may lead to slight overestimation of the ARF. The 
ARF for the three loci combined was calculated by allowing for the possibility of simultaneous 
exposure to several of the risk genotypes. 
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Supplementary material 
 
Supplementary Table 1. Stage 1 SNP exclusion. Detailed breakdown of 
the SNPs that did not pass the quality control or were monomorphic 
and therefore not entered subsequent analysis. 
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Supplementary Table 2. Stage 1 association results 
 
These 13 SNPs showed nominally significant association and were selected for replication. Chr, 
Chromosome; HWE, P value for the deviation from Hardy-Weinberg-Equilibrium; MAF, minor allele 
frequency; OR, odds ratio; CI, confidence interval; Pnom, nominal P value. Genome positions (Genome 
pos) refer to the Human March 2006 (hg18) assembly (http://genome.ucsc.edu/index.html). [gene] 
denotes intergenic position of SNP. HapMap refers to HapMap rel21a_NCBI_Build35 
(http://www.hapmap.org). Minor allele annotation refers to HapMap data. Nominal P values were 
calculated using logistic regression implementing Armitage trend test and taking sex and age as 
covariates into account. Odds ratios and confidence limits were calculated from logistic regression. P 
values resulting from this regression were further corrected for population stratification by dividing the 
resulting χ2 by the inflation factor λ, i.e. by dividing with 1.09. Pcorrected, P value corrected for multiple 
testing using Bonferroni (B). 
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Supplementary Table 3. Stage 2a and 2b SNP selection. 
 
28 SNPs that were chosen for genotyping in stage 2a and 2b (13 SNPs from stage 1 and 15 additional 
SNPs). The additional SNPs were selected based on LD structure: We choose one of the original 
SNPs for each of the six regions and sought one SNP with an r2-value of ≥ 0.9 as a technical replicate, 
two SNPs with an r2 ≈ 0.8 and two SNPs with an r2 ≈ 0.7 upstream and downstream, respectively, of 
the original SNP. In regions where these criteria could not be met, neighbouring SNPs with maximum 
r2 obtainable in this region were chosen. 
+ indicates successfully genotyped. Genome positions (Genome pos) refer to the Human March 2006 
(hg18) assembly (http://genome.ucsc.edu/index.html). * SNP, reference SNP from which the distance 
within the region was computed. r2, r2-values between the reference *SNP and its respective 
neighboring SNPs as downloaded from HapMap rel21a_NCBI_Build35 (http://www.hapmap.org). ** 
not genotyped in stage 2 because no PCR-primer could be designed. 
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Supplementary Table 4. Stage 2a association results. 
 
 
 
 
Chr, Chromosome; HWE, P value for the deviation from Hardy-Weinberg-Equilibrium; MAF, minor 
allele frequency; OR, odds ratio; CI, confidence interval; Pnom, nominal P value. Genome positions 
(Genome pos) refer to the Human March 2006 (hg18) assembly (http://genome.ucsc.edu/index.html). 
HapMap refers to HapMap rel21a_NCBI_Build35 (http://www.hapmap.org). Minor allele annotation 
refers to HapMap data. Nominal P values were calculated using logistic regression implementing 
Armitage trend test and correcting for population stratification. Pcorrected, P value corrected for multiple 
testing using Westfall-Young method (WY). 
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Supplementary Table 5. Stage 2b association results. 
 
 
 
 
 
 
 
Chr, Chromosome; HWE, P value for the deviation from Hardy-Weinberg-Equilibrium; MAF, minor 
allele frequency; OR, odds ratio; CI, confidence interval; Pnom, nominal P value. Genome positions 
(Genome pos) refer to the Human March 2006 (hg18) assembly (http://genome.ucsc.edu/index.html). 
HapMap refers to HapMap rel21a_NCBI_Build35 (http://www.hapmap.org). Minor allele annotation 
refers to HapMap data. Nominal P values were calculated using logistic regression implementing 
Armitage trend test and correcting for population stratification. Pcorrected, P value corrected for multiple 
testing using Westfall-Young method (WY). 
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Supplementary Table 6. Delineation of genetic model. 
 
 
Chr, Chromosome; OR, odds ratio; CI, confidence interval. Odds ratios were obtained using logistic 
regression with age, sex and samples as covariates in the combined stage 1 and 2a and b samples. 
 
 
 
 
 
 
Supplementary Table 7. Analysis of familial versus sporadic cases in 
combined 1 and stage 2a data set. 
 
 
 
Chr, Chromosome, OR, odds ratio; CI, confidence interval. Odds ratios were obtained using logistic 
regression with age and sex as covariates in the combined stage 1 and 2a samples. Nominal P values 
for differences between familial and sporadic cases were tested using Fisher`s exact test on the allele 
counts in familial and sporadic cases, respectively. 
 
Genetics of RLS 
 
 78  78 
Supplementary Table 8. Description of study subjects. 
 
Table includes only successfully genotyped samples. N, number; AaO= age at onset of the disease; 
GER, German; CAN, Canadian. KORAS3/F3 and KORAS4, controls drawn from KORA population-
based cohort study, Germany. 
AaO is unknown for 13 cases (7 females, 6 males) in CAN, 21 (15 females, 6 males) in GER1 and 39 
cases (30 females, 9 males) in GER2.  
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Supplementary Table 9: Oligonucleotide sequences for replication and 
finemapping. 
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Supplementary Table 9: continued 
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Supplementary Table 9: continued. 
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VI. Discussion 
Four studies have been presented that explored issues of diagnosis, treatment and 
pathophysiology in RLS. While one of the studies is currently in press, the three other studies 
have already been published and in the following the results of these studies will be 
discussed taking into account new empirical results that have become available since the 
original publications. 
 
Cognitive functioning in RLS 
Our study on cognitive functioning in RLS has shown deficits in short-term attention and 
verbal fluency in unmedicated subjects with clinically significant RLS. In particular, 
performance in the Stroop task, the d2-cancellation task and phonemic and semantic fluency 
was found decreased in RLS subjects. These results have been discussed in relation to the 
four fully published studies1-4 in this area in Chapter II but beside these, three other research 
groups have presented preliminary results about cognitive functioning in RLS at various 
scientific meetings. Trygvadottir and the research group from Reykjavic5 presented an 
abstract describing cognitive function testing in 19 RLS patients (5 males, 14 females, 22-55 
years, mean age 41) and 18 controls matched for age, sex, and occupation. Sixteen of the 
patients were drug naïve and no information was available regarding drug status of the 
remaining three or severity and aetiology of RLS (idiopathic versus secondary RLS). Tests 
included the Stroop task, verbal fluency, and the sub-tests matrix reasoning and similarities 
from the Wechsler Adult Intelligence Scale. In addition, five computerised tests from the 
CANTAB expedio system, presumably focusing on planning, and tasks assessing selective 
and sustained attention, flexibility of attention, spatial working memory, and reaction time 
were given but were not described in detail. The RLS patients performed significantly worse 
than the healthy controls on the tests of verbal fluency, reaction time, and sustained and 
selective attention. The authors also noted a trend towards worse performance on other tests 
of executive functioning.  
Ferini-Strambi and co-workers6  conducted at study exploring attention, memory, executive 
functions, visuoconstructive and motor abilities in twelve patients (4 males, 8 females, 31 to 
62 years, mean age 49) with idiopathic RLS and documented PLMS and 12 matched healthy 
controls. In addition, patients and controls did not differ in years of education, subjective 
daytime sleepiness (ESS) or depressed mood (BDI). Polysomnography in both groups 
revealed decreased total sleep time and sleep efficacy, and increased sleep onset latency in 
RLS patients compared to controls. Both the number of PLM and PLM associated arousal 
per hour of sleep was higher in patients than in controls while the number of arousals per 
hour of sleep did not differ. Ferini-Strambi assessed sustained attention (TR2) and short-term 
attention (number cancellation, TMT-A and B, Stroop task, digit and block span). In addition, 
working memory was tested with the digit span backward, and visual-spatial learning (Corsi 
supraspan), verbal long-term memory, verbal fluency, visuoconstructive abilities (copy of 
Rey’s complex figure), and motor abilities (Purdue Pegboard) were explored. Compared to 
controls RLS patients showed decreased performance in the test of sustained attention, in 
the Corsi supraspan test, in the digit span forward, and in the Purdue Pegboard task. In the 
same study, also a comparable group with PLMS but no RLS had been included and these 
patients showed decreased performance in very same tasks. Overall, however, performance 
was lowest in the RLS group which lead the author to speculate that the effect of sleep 
deprivation and sleep fragmentation (RLS and PLMS) causes greater neurocognitive 
consequences than sleep fragmentation alone (PLMS).  
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Weniger et al.7 from Göttingen evaluated psychiatric co-morbidity and neuropsychological 
function in 28 RLS patients and 28 healthy controls. Age, gender, or treatment status of the 
participants was not stated in the meeting abstract, but twelve of the RLS patients had at 
least one psychiatric diagnosis. Neuropsychological tasks evaluated general cognitive 
functioning, different aspects of attention, and explicit and implicit visual and verbal memory 
but not details as to the specific tasks were given. RLS patients did not differ from controls in 
attention tasks but both RLS patients with and without psychiatric co-morbidity showed 
impairments in explicit visual and verbal memory.  
Taking all studies together, it is apparent that the area of attention and executive functioning 
has received most of the attention while memory, motor function, or visuoconstructive 
performance have only been assessed in a few of the studies. For the memory domain not 
enough evidence has accumulated to draw any conclusions. Even given the focus on the 
attention tasks, there is no single task that has been applied in more than two studies. 
Nevertheless, with the exception of one study7, all other studies reported at least one 
attention task with reduced performance of RLS subjects when compared to controls. 
Converging results were obtained for simple reaction time and sustained attention. In 
addition, while the more central executive functions such as planning and concept formation 
did not differ between RLS patients and controls there is now consistent indication that verbal 
fluency is an area with decreased performance in RLS patients.   
 
Placebo effect in RLS treatment studies 
Recent years have seen the emergence of a number of substances for the treatment of RLS8 
and with several pivotal studies conducted it soon became apparent that the improvement of 
RLS symptoms in the placebo groups was substantial9,10.  Our meta-analysis has quantified 
the magnitude of the placebo response in RLS treatment studies by combining results from 
24 studies conducted during the last 25 years (Chapter III). The pooled placebo response 
rate for all studies was 40% (vs. 68% in the treatment groups) with response being defined 
as a physician rating of “much” or “very much improved” in the majority of trials. Meta-
regression of placebo response rates revealed a strong effect of study duration on response 
rates that were increasing over time. The estimated placebo response rate was 22% at the 
end of the first week and expected to increase by 3% for each additional week. At the time of 
the study conduction no placebo-controlled trials longer than twelve weeks were available. In 
the meantime, results from a double-blind placebo-controlled trial with 26 weeks duration 
have become available11. In this study with 205 RLS patients in the placebo group and 196 
patients receiving ropinirole, the response rate after 12 weeks was 52% in the placebo group 
and 68% in the treatment group. After 26 weeks response rates rose to 64% and 84%, 
suggesting that the placebo response is also increasing over periods longer than 12 weeks, 
although the rate of improvement over time appears to be attenuated for longer periods.  
In addition, there was a large placebo effect in RLS severity as measured by the IRLS while 
other scores of RLS severity had a lower – small to moderate – placebo effect that was lower 
in cross-over trials than in parallel group trials. This difference between cross-over and 
parallel group trials could not be analyzed for the IRLS since 13 of the 14 trials that employed 
the IRLS were parallel group trials. Recent studies, however, have provided a striking 
example for the magnitude of this effect. In the last year, two short-term studies have 
explored the effect of gabapentin enarcabil on RLS symptoms12,13. Gabapentin enarcabil is a 
precursor to gabapentin that allows for the rapid absorption through the gastrointestinal tract 
before being converted into gabapentin and overcomes gabapentin’s unfavorable 
pharmacokinetic profile and dose-dependent bioavailability. Both studies had a highly similar 
study design including a study length of 14 days with the only major difference being that one 
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study12 was a cross-over design while the other13 was conducted with a parallel group 
design. The cross-over study enrolled 38 subjects and found that mean change after 14-days 
of placebo was only -1.9 points on the 40-point IRLS scale (vs. -12.1 for gabapentin 
enarcabil). In the parallel-group study 29 subjects received gabapentin enarcabil and 33 
received placebo and the mean change in IRLS after 14 days was -8.9 (vs. -16.1 for the 
active treatment). Similar, response rates were 14.7% (vs. 79.5%) in the cross-over trial but 
48.5% (vs. 81.3%) in the parallel-group trial.  
While the magnitude of the placebo response in RLS seems substantial it is not out of 
proportion when compared to other disorders of the central nervous system with which it 
shares some features. For example, a recent meta-analysis14 involving 11 studies and 858 
patients with Parkinson’s Disease (PD) showed an overall response rate of 16% with a range 
of 0 to 55%. However, considering only surgical trials, a positive placebo response was 
observed in 42% of PD patients.  Migraine like RLS is episodic and sensory in nature. Here a 
meta-analysis15 showed an average headache placebo response rate of 30%. Although no 
overall response rates are available for insomnia, a meta-analysis16 has demonstrated a 
substantial placebo effect in both subjective and objective sleep parameters and this placebo 
response also increases with time17 as with RLS. Finally, in depression the proportion of 
patients who respond to placebo has been estimated as 30%18.  While the 40% placebo 
response rate in RLS seems in the upper range compared to these disorders, it has to be  
taken into account that treatment response rates vary correspondingly. For example, the 
30% placebo response rate is matched with a 50% treatment response rate in depression18, 
and with a 60% rate in migraine patients15. These are ratios of placebo to treatment response 
of 0.6 and 0.5 which again is comparable to the ratio of 0.58 for RLS (40% placebo 
response, 68% treatment response). 
Certainly the most pressing question at the moment is that of the “real” size of the placebo 
effect. So far, the placebo response has been conceptualized as the before-after difference 
observed in the placebo group. Without a proper control condition, however, there is no way 
to distinguish the effect of the placebo from the natural course of the disease, regression to 
the mean or other factors that operate in a time-dependent manner19. So far, we have no 
valid estimates about what is the expected rate of spontaneous significant improvement or 
remission in RLS. This rate, however, will critically determine the size of true placebo effect 
and hence effective ways to cope with it. Conceptually, beside the inclusion of a no-treatment 
control group there are also other less obvious paradigms to obtain an estimate of the true 
placebo effect such as the open and hidden administration of a treatment20.  In this latter 
paradigm a patient either fully views a treatment or receives it in a “hidden” manner without 
any cues for example by means of a computer-programmed drug infusion pump with no 
clinician present and the patient unaware that treatment is being administered21. With respect 
to pain, the difference in medication needed for analgesia between open and hidden 
injections reflects the placebo analgesic effect. It is important to stress that the size of the 
real placebo effect is more than a purely academic question given the seminal and 
provocative work of Hróbjartsson and Gøtsche22 that showed that in many instances a 
placebo effect is no longer apparent when compared to a non-treatment control condition in 
several conditions.  A notable exception to this is experimental pain or pain disorders where 
placebo exerts a powerful effect even compared to no-treatment control groups.   
Other questions concern potential moderators of the placebo response. For most of the 
outcome parameters in RLS trials there was significant between-study heterogeneity. 
Moderators of the placebo response were trial duration and study design. Nothing is known 
so far about other important variables that might explain within study variability such as 
severity of RLS, pre-medication status, familiar vs. sporadic RLS and other subject-specific 
characterizations. Also, the placebo response in special populations such as the elderly or 
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children with RLS has not been explored so far. Although there are only a very limited 
number of double-blind placebo-controlled treatment trials in secondary RLS the placebo 
responses appear to be considerably smaller at least in uremic RLS23,24.   
It is important to stress that the existence or magnitude of a placebo effect does neither say 
anything about RLS being a “real” vs. “imagined” condition, nor necessarily about the quality 
of the trial. Indeed, the conceptualization of the placebo effect has shifted from the focus on 
the inert content of a physical placebo agent to the overall simulation of a therapeutic 
intervention including for example the interaction between patient and medical personnel. In 
recent years, research has identified many types of placebo responses driven by different 
mechanisms depending on the particular context wherein the placebo is given20. Some 
placebo responses, such as analgesia, are initiated and maintained by expectations of 
symptom change and changes in motivation/emotion. Placebo factors have neurobiological 
underpinnings and actual effects on the brain and body. They are not just response biases. 
Other placebo responses result from less conscious processes, such as classical 
conditioning in the case of immune, hormonal, and respiratory functions20. Intriguingly, the 
two systems that play a crucial role in the physiological response to a placebo are the 
dopamine and the opioid systems25. The unique responsiveness of RLS to both 
dopaminergic agents and opioids places it right at the crossroad of these two systems.  
 
 
Prevalence of RLS in transsexual patients 
Epidemiological studies have shown a markedly higher prevalence of RLS in women26,27 and 
this increased risk for RLS in females has been related to the number of pregnancies27. A 
recent study28 found markedly elevated estradiol levels in pregnant women with RLS during 
late-term pregnancy but not after delivery when subjects were symptom-free. This has 
prompted us to elucidate the role of gender and steroid hormones as a risk factor for RLS by 
exploring the prevalence of RLS symptoms in a large group of transsexual patients treated 
with either testosterone or estrogens. Contrary to our hypothesis there was no statistically 
significant difference in RLS prevalence between the two groups and the numerically higher 
prevalence in the estrogen-treated group could be explained by the higher average age in 
this group. In addition, we did not observe a systematic relationship between the onset of 
RLS and the onset of hormonal treatment.  
While the study was most likely underpowered to reveal significant differences and neglected 
to obtain information about transient RLS symptoms, another explanation for this lack of 
findings could be the dosage of hormonal treatment in this group. In male-to-female 
transsexuals estradiol levels range in general from 100 to 200 pg/ml, dependent on the 
dosage and time of substitution, as compared to 50-500 pg/ml found during the menstrual 
cycle. This is considerably lower than estradiol levels found during pregnancy and in the 
study 8 on pregnant females with and without RLS levels of estradiol were up to 100 times 
higher (15,000 to 45,000 pg/ml) than those found during the menstrual cycle.  
This is corroborated by studies involving hormone replacement therapy (HRT) where 
estradiol levels are increased but considerably lower than during pregnancy. Here, two 
epidemiological studies29,30 failed to find a more frequent use of HRT in women with RLS. 
RLS symptoms are not routinely included into the assessment during HRT trials and it is 
therefore unknown what would be the incidence of new-onset RLS in subjects undergoing 
HRT. However, In a  one year trial31 only one of the 73 (1.4%) women dropped out because 
of the new onset of RLS, which would suggest a low incidence of RLS during HRT. Although 
in a sleep lab population one study32 found that HRT was more frequent in patients with RLS 
(74%) than in patients without RLS (48%), several other polysomnographic investigations33-35 
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of HRT failed to find an influence on periodic leg movements, a closely associated 
characteristic of RLS.   
Taken together, at the present moment the available evidence does not argue conclusively 
for a role of low-dose estrogens in the pathophysiology of RLS. However, while estrogens 
might not be a necessary and/or sufficient factor to elicit and maintain RLS, it is still 
conceivable that estrogens may be a trigger in subjects with a pre-existing, probably 
genetically-based, vulnerability to RLS.   
 
Genome-wide association study in RLS 
Our genome-wide association study found that genetic variants in MEIS1, BTBD9, and 
LBXCOR1/MAP2K5 were associated with an increased risk for developing RLS36. Previous 
linkage studies in families with RLS had identified eight loci that are associated with RLS but 
no causally related sequence has yet been identified37. These loci, named RLS1 to RLS8, 
are located on chromosomes 12q, 14q, 9p, 20p, 2q, 4q, 17p and 19p, respectively. In these 
studies the apparent genetic heterogeneity of RLS has made linkage studies notoriously 
difficult which favors association approaches. Our initial genome-wide screen for common 
variants in 400 cases and 1,600 controls enabled us to detect risk alleles with odds ratios > 
1.5 and the substantially increased sample size in the replicate study has and provided 
unequivocal evidence for the signals. A particular feature of our study design was the use of 
a control group from the general population. This provided us with very accurate estimates of 
the genotype frequencies and it avoided any bias to which a disease-negative population is 
prone. 
At the time of publication, BTBD9 was independently identified in another genome-wide 
association study of an Icelandic population38. Their phenotypic assessment included the 
measurement of PLM and, interestingly, the association with BTBD9 was found in subjects 
with periodic leg movements (PLM) without RLS but not in subjects with RLS without PLMs. 
Interestingly, in the Icelandic study a 13% further reduction of serum ferritin levels was found 
in the RLS group, implicating BTBD9 in iron storage. Since then, the three genetic variants 
MEIS1, BTBD9 and LBXCOR1/MAP2K5 have been independently replicated in three 
European populations39 and a further genome-wide association study has identified PTPRD 
(protein tyrosine phosphatase receptor type delta) as another genetic variant associated with 
RLS40.  Studies in other disorders have found recently an association between BTBD9 and 
Tourette’s syndrome in a candidate gene study41.  
Apart from one association with body iron stores38, in the genome-wide association studies 
no genes could be identified that were related to the iron, dopamine or endogenous opioid 
systems. The functions of the five genes that were identified—MEIS1, BTBD9, 
MAP2K5/LBXCOR1, and PTPRD—are largely related to embryonic neuronal development, 
and no functional relationships with RLS have so far been established. At this point one can 
only speculate about possible relations between the genetics and RLS. The genome-wide 
association studies are not exhaustive in identifying genetic factors contributing to RLS and 
further investigations are expected to contribute towards a better picture of what constitutes 
the genetic architecture of the complex phenotype of restless legs syndrome.  
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